Myocardial substrate metabolism in the normal and failing heart

Physiological Reviews

Volumn 85, Issue 3, 2005, Pages 1093-1129

  Stanley, William C ^a   Recchia, Fabio A ^b   Lopaschuk, Gary D ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACYLGLYCEROL LIPASE; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARNITINE; DEOXYCORTICOSTERONE ACETATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; HEART ENZYME; INSULINOMIMETIC GLUCAGON LIKE PEPTIDE 1; KETONE BODY; METOPROLOL; NITRIC OXIDE; OXFENICINE; PEPTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; ROSIGLITAZONE; TRIACYLGLYCEROL; TRIMETAZIDINE; UBIQUINONE; UNCLASSIFIED DRUG;

AGING; CARBOHYDRATE METABOLISM; CLINICAL TRIAL; DIET SUPPLEMENTATION; DISEASE COURSE; DOWN REGULATION; ELECTRON TRANSPORT; FATTY ACID OXIDATION; GLUCOSE OXIDATION; GLYCOLYSIS; HEART FAILURE; HEART FUNCTION; HEART MUSCLE METABOLISM; HEART VENTRICLE REMODELING; HUMAN; LONG TERM CARE; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY CHAIN; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; HEART; HEART FAILURE, CONGESTIVE; HUMANS; METABOLISM; MYOCARDIUM; PHENOTYPE;

EID: 21244492310     PISSN: 00319333     EISSN: None     Source Type: Journal    
DOI: 10.1152/physrev.00006.2004     Document Type: Review

References (520)

1. Abel ED, Kaulbach HC, Tian R, Hopkins JC, Duffy J, Doetschman T, Minnemann T, Boers ME, Hadro E, Oberste-Berghaus C, Quist W, Lowell BB, Ingwall JS, and Kahn BB. Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart. J Clin Invest 104: 1703-1714, 1999.
2. Abu-Elheiga L, Matzuk MM, Abo-Hashema KA, and Wakil SJ. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science 291: 2613-2616, 2001.
3. Abu-Erreish GM, Neely JR, Whitmer JT, Whitman V, and Sanadi DR. Fatty acid oxidation by isolated perfused working hearts of aged rats. Am J Physiol Endocrinol Metab Gastrointest Physiol 232: E258-E262, 1977.
4. Almeida A, Moncada S, and Bolanos JP. Nitric oxide switches on glycolysis through the AMP protein kinase and 6-phosphofructo-2-kinase pathway. Nat Cell Biol 6: 45-51, 2004.
5. Andersson B, Blomstrom-Lundqvist C, Hedner T, and Waagstein F. Exercise hemodynamics and myocardial metabolism during long-term beta-adrenergic blockade in severe heart failure. J Am Coll Cardiol 18: 1059-1066, 1991.
6. Angeja BG and Grossman W. Evaluation and management of diastolic heart failure. Circulation 107: 659-663, 2003.
7. Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, Cohn JN, and Yusuf S. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 361: 1077-1083, 2003.
8. Arad M, Benson DW, Perez-Atayde AR, McKenna WJ, Sparks EA, Kanter RJ, McGarry K, Seidman JG, and Seidman CE. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest 109: 357-362, 2002.
9. Arad M, Moskowitz IP, Patel W, Ahmad F, Perez-Atayde AR, Sawyer DB, Walter M, Li GH, Burgon PG, Maguire CT, Stapleton D, Schmitt JP, Guo XX, Pizard A, Kupershmidt S, Roden DM, Berul CI, Seidman CE, and Seidman JG. Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation 107: 2850-2856, 2003.
10. Arnolda LF, Llewellyn-Smith IJ, and Minson JB. Animal models of heart failure. Aust N Z J Med 29: 403-409, 1999.
11. Aschenbach WG, Brower GL, Talmadge RJ, Dobson JL, and Gladden LB. Effect of a myocardial volume overload on lactate transport in skeletal muscle sarcolemmal vesicles. Am J Physiol Regul Integr Comp Physiol 281: R176-R186, 2001.
12. Ashrafian H. Cardiac energetics in congestive heart failure. Circulation 105: e44-e45, 2002.
13. Augustus AS, Kako Y, Yagyu H, and Goldberg IJ. Routes of FA delivery to cardiac muscle: modulation of lipoprotein lipolysis alters uptake of TG-derived FA. Am J Physiol Endocrinol Metab 284: E331-E339, 2003.
14. Aurigemma GP and Gaasch WH. Clinical practice. Diastolic heart failure. N Engl J Med 351: 1097-1105, 2004.
15. Avogaro A, Nosadini R, Doria A, Fioretto P, Velussi M, Vigorito C, Sacca L, Toffolo G, Cobelli C, and Trevisan R. Myocardial metabolism in insulin-deficient diabetic humans without coronary artery disease. Am J Physiol Endocrinol Metab 258: E606-E618, 1990.
16. Bache RJ, Zhang J, Path G, Merkle H, Hendrich K, From AH, and Ugurbil K. High-energy phosphate responses to tachycardia and inotropic stimulation in left ventricular hypertrophy. Am J Physiol Heart Circ Physiol 266: H1959-H1970, 1994.
17. Balaban RS. Regulation of oxidative phosphorylation in the mammalian cell. Am J Physiol Cell Physiol 258: C377-C389, 1990.
18. Balaban RS, Kantor HL, Katz LA, and Briggs RW. Relation between work and phosphate metabolite in the in vivo paced mammalian heart. Science 232: 1121-1123, 1986.
19. Barakat H, Brown W, and Henry SD. Studies of fatty acid oxidation in homogenates of the cardiomyopathic hamster. Life Sci 23: 1835-1840, 1978.
20. Barger PM and Kelly DP. Fatty acid utilization in the hypertrophied and failing heart: molecular regulatory mechanisms. Am J Med Sci 318: 36-42, 1999.
21. Bashore TM, Magorien DJ, Letterio J, Shaffer P, and Unverferth DV. Histologic and biochemical correlates of left ventricular chamber dynamics in man. J Am Coll Cardiol 9: 734-742, 1987.
22. Beer M, Seyfarth T, Sandstede J, Landschutz W, Lipke C, Kostler H, von Kienlin M, Harre K, Hahn D, and Neubauer S. Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with (31)P-SLOOP magnetic resonance spectroscopy. J Am Coll Cardiol 40: 1267-1274, 2002.
23. Belardinelli R and Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Eur Heart J 22: 2164-2170, 2001.
24. Belke DD, Larsen TS, Lopaschuk GD, and Severson DL. Glucose and fatty acid metabolism in the isolated working mouse heart. Am J Physiol Regul Integr Comp Physiol 277: R1210-R1217, 1999.
25. Berger J and Moller DE. The mechanisms of action of PPARs. Annu Rev Med 53: 409-435, 2002.
26. Bergman G, Atkinson L, Metcalfe J, Jackson N, and Jewitt DE. Beneficial effect of enhanced myocardial carbohydrate utilisation after oxfenicine (L-hydroxyphenylglycine) in angina pectoris. Eur Heart J 1: 247-253, 1980.
27. Bersin RM and Stacpoole PW. Dichloroacetate as metabolic therapy for myocardial ischemia and failure. Am Heart J 134: 841-855, 1997.
28. Bersin RM, Wolfe C, Kwasman M, Lau D, Klinski C, Tanaka K, Khorrami P, Henderson GN, de Marco T, and Chatterjee K. Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J Am Coll Cardiol 23: 1617-1624, 1994.
29. Bielefeld DR, Vary TC, and Neely JR. Inhibition of carnitine palmitoyl-CoA transferase activity and fatty acid oxidation by lactate and oxfenicine in cardiac muscle. J Mol Cell Cardiol 17: 619-625, 1985.
30. Bing RJ. The metabolism of the heart. Harvey Lect 50: 27-70, 1955.
31. Bing RJ, Siegel A, Vitale A, Taeschler M, Balboni FSE, Klappe M, and Edwards S. Metabolic studies on the human heart in vivo. I. Studies on carbohydrate metabolism of the human heart. Am J Med 15: 284-296, 1953.
32. Bing RJ, Siegel A, Ungar I, and Gilbert M. Metabolism of the human heart. II. Studies on fat, ketone and amino acid metabolism. Am J Med 16: 504-515, 1954.
33. Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers JW, Witteman JC, and Stricker BH. Quantifying the heart failure epidemic: prevalence, incidence rate, life-time risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 25: 1614-1619, 2004.
34. Borst PLJA, Christ EJ, and Slater EC. Uncoupling activity of long-chain fatty acids. Biochim Biophys Acta 62: 509-518, 1964.
35. Botker HE, Helligso P, Kimose HH, Thomassen AR, and Nielsen TT. Determination of high energy phosphates and glycogen in cardiac and skeletal muscle biopsies, with special reference to influence of biopsy technique and delayed freezing. Cardiovasc Res 28: 524-527, 1994.
36. Bowker-Kinley MM, Davis WI, Wu P, Harris RA, and Popov KM. Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochem J 329; 191-196, 1998.
37. Brand MD, Brindle KM, Buckingham JA, Harper JA, Rolfe DF, and Stuart JA. The significance and mechanism of mitochondrial proton conductance. Int J Obes Relat Metab Disord 23 Suppl 6: S4-S11, 1999.
38. Bristow M. Etomoxir: a new approach to treatment of chronic heart failure. Lancet 356: 1621-1622, 2000.
39. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, and Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Invest Circ 94: 2807-2816, 1996.
40. Broderick TL, Quinney HA, and Lopaschuk GD. Carnitine stimulation of glucose oxidation in the fatty acid perfused isolated working rat heart. J Biol Chem 267: 3758-3763, 1992.
41. Brown NF, Weis BC, Husti JE, Foster DW, and McGarry JD. Mitochondrial carnitine palmitoyltransferase I isoform switching in the developing rat heart. J Biol Chem 270: 8952-8957, 1995.
42. Brownsey RW, Boone AN, and Allard MF. Actions of insulin on the mammalian heart: metabolism, pathology and biochemical mechanisms. Cardiovasc Res 34: 3-24, 1997.
43. Brune B and Lapetina EG. Activation of a cytosolic ADP-ribosyl- transferase by nitric oxide-generating agents. J Biol Chem 264: 8455-8458, 1989.
44. Buchwald A, Till H, Unterberg C, Oberschmidt R, Figulla HR, and Wiegand V. Alterations of the mitochondrial respiratory chain in human dilated cardiomyopathy. Eur Heart J 11: 509-516, 1990.
45. Budingen T. Uber die Moglichkeit einer Ernahrungsbehandlung des Herzmuskels durch Einbringen von Traubenzuckerlosunger in den grober Kreislauf. Dt Arch Klin Med 114: 534-579, 1914.
46. Bunger R, Mallet RT, and Hartman DA. Pyruvate-enhanced phosphorylation potential and inotropisrn in normoxic and post-ischemic isolated working heart. Near-complete prevention of reperfusion contractile failure. Eur J Biochem 180: 221-233, 1989.
47. Burkhoff D, Weiss RG, Schulman SP, Kalil-Filho R, Wannenburg T, and Gerstenblith G. Influence of metabolic substrate on rat heart function and metabolism at different coronary flows. Am J Physiol Heart Circ Physiol 261: H741-H750, 1991.
48. Campbell FM, Kozak R, Wagner A, Altarejos JY, Dyck JR, Belke DD, Severson DL, Kelly DP, and Lopaschuk GD. A role for peroxisome proliferator-activated receptor alpha (PPARalpha) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J Biol Chem 277: 4098-4103, 2002.
49. Casademont J and Miro O. Electron transport chain defects in heart failure. Heart Failure Rev 7: 131-139, 2002.
50. Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, Wang W, Skettino SL, and Wolff AA. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 291: 309-316, 2004.
51. Chandler MP, Chavez PN, McElfresh TA, Huang H, Harmon CS, and Stanley WC. Partial inhibition of fatty acid oxidation increases regional contractile power and efficiency during demand-induced ischemia. Cardiovasc Res 59: 143-151, 2003.
52. Chandler MP, Kerner J, Huang H, Vazquez E, Reszko A, Martini WZ, Hoppel CL, Imai M, Rastogi S, Sabbah HN, and Stanley WC. Moderate severity heart failure does not involve a downregulation of myocardial fatty acid oxidation. Am J Physiol Heart Circ Physiol 287: H1538-H1543, 2004.
53. Chandler MP, Stanley WC, Morita H, Suzuki G, Roth BA, Blackburn B, Wolff A, and Sabbah HN. Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure. Circ Res 91: 278-280, 2002.
54. Chavez PN, Stanley WC, McElfresh TA, Huang H, Sterk JP, and Chandler MP. Effects of hyperglycemia and fatty acid oxidation inhibition during aerobic conditions and demand-induced ischemia. Am J Physiol Heart Circ Physiol H1521-H1527, 2003.
55. Cheema-Dhadli S, Robinson BH, and Halperin ML. Properties of the citrate transporter in rat heart: implications for regulation of glycolysis by cytosolic citrate. Can J Biochem 54: 561-565, 1976.
56. Chen V, Wagner G, and Spitzer JJ. Regulation of substrate oxidation in isolated myocardial cells by beta-hydroxybutyrate. Horm Metab Res 16: 243-247, 1984.
57. Chen ZP, Mitchelhill KI, Michell BJ, Stapleton D, Rodriguez-Crespo I, Witters LA, Power DA, Ortiz de Montellano PR, and Kemp BE. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett 443: 285-289, 1999.
58. Cheng L, Ding G, Qin Q, Huang Y, Lewis W, He N, Evans RM, Schneider MD, Brako FA, Xiao Y, Chen YE, and Yang Q. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 10: 1245-1250, 2004.
59. Chiu HC, Kovacs A, Ford DA, Hsu FF, Garcia R, Herrero P, Saffitz JE, and Schaffer JE. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 107: 813-822, 2001.
60. Clapham JC, Arch JR, Chapman H, Haynes A, Lister C, Moore GB, Piercy V, Carter SA, Lehner I, Smith SA, Beeley LJ, Godden RJ, Herrity N, Skehel M, Changani KK, Hockings PD, Reid DG, Squires SM, Hatcher J, Trail B, Latcham J, Rastan S, Harper AJ, Cadenas S, Buckingham JA, Brand MD, and Abuin A. Mice overexpressing human uncoupling protein-3 in skeletal muscle are hyperphagic and lean. Nature 406: 415-418, 2000.
61. Clarke B, Wyatt KM, and McCormack JG. Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism. J Mol Cell Cardiol 28: 341-350, 1996.
62. Cline GW, Vidal-Puig AJ, Dufour S, Cadman KS, Lowell BB, and Shulman GI. In vivo effects of uncoupling protein-3 gene disruption on mitochondrial energy metabolism. J Biol Chem 276: 20240-20244, 2001.
63. Coats AJ. Angiotensin type-1 receptor blockers in heart failure. Prog Cardiovasc Dis 44: 231-242, 2002.
64. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, and Wright TJ. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Failure 5: 659-667, 2003.
65. Coleman RA, Lewin TM, and Muoio DM. Physiological and nutritional regulation of enzymes of triacylglycerol synthesis. Annu Rev Nutr 20: 77-103, 2000.
66. Collins-Nakai RL, Noseworthy D, and Lopaschuk GD. Epinephrine increases ATP production in hearts by preferentially increasing glucose metabolism. Am J Physiol Heart Circ Physiol 267: H1862-H1871, 1994.
67. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, and Lukas MA. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation 94: 2800-2806, 1996.
68. Comte B, Vincent G, Bouchard B, Benderdour M, and des Rosiers C. Reverse flux through cardiac NADP(+)-isocitrate dehydrogenase under normoxia and ischemia. Am J Physiol Heart Circ Physiol 283: H150S-H1514, 2002.
69. 13C labeling of citrate released by perfused rat hearts. J Biol Chem 272: 26117-26124, 1997.
70. Cottin Y, Lhuillier I, Gilson L, Zeller M, Bonnet C, Toulouse C, Louis P, Rochette L, Girard C, and Wolf JE. Glucose insulin potassium infusion improves systolic function in patients with chronic ischemic cardiomyopathy. Eur J Heart Failure 4: 181-184, 2002.
71. Coven DL, Hu X, Cong L, Bergeron R, Shulman GI, Hardie DG, and Young LH. Physiological role of AMP-activated protein kinase in the heart: graded activation during exercise. Am J Physiol Endocrinol Metab 285: E629-E636, 2003.
72. Crass MF III. Exogenous substrate effects on endogenous lipid metabolism in the working rat heart. Biochim Biophys Acta 280: 71-81, 1972.
73. Crass MF III. Heart triglyceride and glycogen metabolism: effects of catecholamines, dibutyryl cyclic AMP, theophylline, and fatty acids. Rec Adv Stud Cardiac Struct Metab 3: 275-290, 1973.
74. Crass MF III. Regulation of triglyceride metabolism in the isotopically prelabeled perfused heart. Federation Proc 36: 1995-1999, 1977.
75. Crass MF III and Shipp JC. Metabolism of exogenous and endogenous fatty acids in heart muscle. Rec Adv Stud Cardiac Struct Metab 1: 115-126, 1972.
76. Crass MF III, Shipp JC, and Pieper GM. Effects of catecholamines on myocardial endogenous substrates and contractility. Am J Physiol 228: 618-627, 1975.
77. Dalla-Volta S, Maraglino G, Della-Valentina P, Viena P, and Desideri A. Comparison of trimetazidine with nifedipine in effort angina: a double-blind, crossover study. Cardiovasc Drugs Ther 4 Suppl 4: 853-859, 1990.
78. Davila-Roman VG, Vedala G, Herrero P, de las FL, Rogers JG, Kelly DP, and Gropler RJ. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 40: 271-277, 2002.
79. Davos CH, Doehner W, Rauchhaus M, Cicoira M, Francis DP, Coats AJ, Clark AL, and Anker SD. Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. J Cardiac Failure 9: 29-35, 2003.
80. De las FL, Herrero P, Peterson LR, Kelly DP, Gropler RJ, and Davila-Roman VG. Myocardial fatty acid metabolism: independent predictor of left ventricular mass in hypertensive heart disease. Hypertension 41: 83-87, 2003.
81. Denton RM and Randle PJ. Concentrations of glycerides and phospholipids in rat heart and gastrocnemius muscles. Effects of alloxan-diabetes and perfusion. Biochem J 104: 416-422, 1967.
82. Depre C, Gaussin V, Ponchaut S, Fischer Y, Vanoverschelde JL, and Hue L. Inhibition of myocardial glucose uptake by cGMP. Am J Physiol Heart Circ Physiol 274: H1443-H1449, 1998.
83. Depre C and Hue L. Cyclic GMP in the perfused rat heart. Effect of ischaemia, anoxia and nitric oxide synthase inhibitor. FEBS Lett 345: 241-245, 1994.
84. Depre C, Rider MH, and Hue L. Mechanisms of control of heart glycolysis. Eur J Biochem 258: 277-290, 1998.
85. Depre C, Shipley GL, Chen W, Han Q, Doenst T, Moore ML, Stepkowski S, Davies PJ, and Taegtmeyer H. Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy. Nat Med 4: 1269-1275, 1998.
86. Depre C, Vanoverschelde JL, Goudemant JF, Mottet I, and Hue L. Protection against ischemic injury by nonvasoactive concentrations of nitric oxide synthase inhibitors in the perfused rabbit heart. Circulation 92: 1911-1918, 1995.
87. De Sousa E, Veksler V, Minajeva A, Kaasik A, Mateo P, Mayoux E, Hoerter J, Bigard X, Serrurier B, and Ventura-Clapier R. Subcellular creatine kinase alterations. Implications in heart failure. Circ Res 85: 68-76, 1999.
88. D'Hahan N, Taouil K, Dassouli A, and Morel JE. Long-term therapy with trimetazidine in cardiomyopathic Syrian hamster BIO 14:6. Eur J Pharmacol 328: 163-174, 1997.
89. 2+ in hearts of cardiomyopathic hamsters. Am J Physiol Heart Circ Physiol 264: H2188-H2197, 1993.
90. Dimmeler S and Brune B. Characterization of a nitric-oxide-catalysed ADP-ribosylation of glyceraldehyde-3-phosphate dehydrogenase. Eur J Biochem 210: 305-310, 1992.
91. Dimmeler S, Lottspeich F, and Brune B. Nitric oxide causes ADP-ribosylation and inhibition of glyceraldehyde-3-phosphate dehydrogenase. J Biol Chem 267: 16771-16774, 1992.
92. Dyck JR, Barr AJ, Barr RL, Kolattukudy PE, and Lopaschuk GD. Characterization of cardiac malonyl-CoA decarboxylase and its putative role in regulating fatty acid oxidation. Am J Physiol Heart Circ Physiol 275: H2122-H2129, 1998.
93. Dyck JR, Cheng JF, Stanley WC, Barr R, Chandler MP, Brown S, Wallace D, Arrhenius T, Harmon C, Yang G, Nadzan AM, and Lopaschuk GD. Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation. Circ Res 94: e78-e84, 2004.
94. Dyck JR, Kudo N, Barr AJ, Davies SP, Hardie DG, and Lopaschuk GD. Phosphorylation control of cardiac acetyl-CoA carboxylase by cAMP-dependent protein kinase and 5′-AMP activated protein kinase. Eur J Biochem 262: 184-190, 1999.
95. Dyck JR and Lopaschuk GD. Malonyl CoA control of fatty acid oxidation in the ischemic heart. J Mol Cell Cardiol 34: 1099-1109, 2002.
96. Dyson E, Sucov HM, Kubalak SW, Schmid-Schonbein GW, DeLano FA, Evans RM, Ross J Jr, and Chien KR. Atrial-like phenotype is associated with embryonic ventricular failure in retinoid X receptor alpha -/- mice. Proc Natl Acad Sci USA 92: 7386-7390, 1995.
97. Dzeja PP, Pucar D, Redfield MM, Burnett JC, and Terzic A. Reduced activity of enzymes coupling ATP-generating with ATP-consuming processes in the failing myocardium. Mol Cell Biochem 201: 33-40, 1999.
98. Dzeja PP, Redfield MM, Burnett JC, and Terzic A. Failing energetics in failing hearts. Curr Cardiol Rep 2: 212-217, 2000.
99. Dzeja PP, Vitkevicius KT, Redfield MM, Burnett JC, and Terzic A. Adenylate kinase-catalyzed phosphotransfer in the myocardium: increased contribution in heart failure. Circ Res 84: 1137-1143, 1999.
100. Eichhorn EJ, Bedotto JB, Malloy CR, Hatfield BA, Deitchman D, Brown M, Willard JE, and Grayburn PA. Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation 82: 473-483, 1990.
101. Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, Hatfield BA, Marcoux LG, and Malloy CR. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 24: 1310-1320, 1994.
102. England PJ and Robinson BH. The permeability of rat heart mitochondria to citrate. Biochem J 112: 8P, 1969.
103. Entman ML, Bornet EP, van Winkle WB, Goldstein MA, and Schwartz A. Association of glycogenolysis with cardiac sarcoplasmic reticulum. II. Effect of glycogen depletion, deoxycholate solubilization and cardiac ischemia: evidence for a phorphorylase kinase membrane complex. J Mol Cell Cardiol 9: 515-528, 1977.
104. Fannin SW, Lesnefsky EJ, Slabe TJ, Hassan MO, and Hoppel CL. Aging selectively decreases oxidative capacity in rat heart interfibrillar mitochondria. Arch Biochem Biophys 372: 399-407, 1999.
105. Fantini E, Demaison L, Sentex E, Grynberg A, and Athias P. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol 26: 949-958, 1994.
106. Fell DA. Increasing the flux in metabolic pathways: a metabolic control analysis perspective. Biotechnol Bioeng 58: 121-124, 1998.
107. Fell DA and Sauro HM. Metabolic control analysis. The effects of high enzyme concentrations. Eur J Biochem 192: 183-187, 1990.
108. Ferrannini E, Santoro D, Bonadonna R, Natali A, Parodi O, and Camici PG. Metabolic and hemodynamic effects of insulin on human hearts. Am J Physiol Endocrinol Metab 264: E308-E315, 1993.
109. Finck BN, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A, Gross RW, and Kelly DP. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci USA 100: 1226-1231, 2003.
110. Fisher DJ, Heymann MA, and Rudolph AM. Myocardial oxygen and carbohydrate consumption in fetal lambs in utero and in adult sheep. Am J Physiol Heart Circ Physiol 238: H399-H405, 1980.
111. Fisher DJ, Heymann MA, and Rudolph AM. Myocardial consumption of oxygen and carbohydrates in newborn sheep. Pediatr Res 15: 843-846, 1981.
112. Fisher DJ, Heymann MA, and Rudolph AM. Regional myocardial blood flow and oxygen delivery in fetal, newborn, and adult sheep. Am J Physiol Heart Circ Physiol 243: H729-H731, 1982.
113. Fontaine KR, Redden DT, Wang C, Westfall AO, and Allison DB. Years of life lost due to obesity. JAMA 289: 187-193, 2003.
114. Forsey RG, Reid K, and Brosnan JT. Competition between fatty acids and carbohydrate or ketone bodies as metabolic fuels for the isolated perfused heart. Can J Physiol Pharmacol 65: 401-406, 1987.
115. Fragasso G, Piatti Md PM, Monti L, Palloshi A, Setola E, Puccetti P, Calori G, Lopaschuk GD, and Margonato A. Short-and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J 146: E18, 2003.
116. From AH. Should manipulation of myocardial substrate utilization patterns be a component of the congestive heart failure therapeutic paradigm? J Card Fail 4: 127-129, 1998.
117. Gaasch WH and Zile MR. Left ventricular diastolic dysfunction and diastolic heart failure. Annu Rev Med 55: 373-394, 2004.
118. Garcia CK, Goldstein JL, Pathak RK, Anderson RG, and Brown MS. Molecular characterization of a membrane transporter for lactate, pyruvate, and other monocarboxylates: implications for the Cori cycle. Cell 76: 865-873, 1994.
119. Garland PB, Randle PJ, and Newsholme EA. Citrate as an intermediary in the inhibition of phosphofructokinase in rat heart muscle by fatty acids, ketone bodies, pyruvate, diabetes, and starvation. Nature 200: 169-170, 1963.
120. Garlid KD, Jaburek M, and Jezek P. The mechanism of proton transport mediated by mitochondrial uncoupling proteins. FEBS Lett 438: 10-14, 1998.
121. Garlid KD, Jaburek M, and Jezek P. Mechanism of uncoupling protein action. Biochem Soc Trans 29: 803-806, 2001.
122. Garlid KD, Jaburek M, Jezek P, and Varecha M. How do uncoupling proteins uncouple? Biochim Biophys Acta 1459: 383-389, 2000.
123. Garlid KD, Orosz DE, Modriansky M, Vassanelli S, and Jezek P. On the mechanism of fatty acid-induced proton transport by mitochondrial uncoupling protein. J Biol Chem 271: 2615-2620, 1996.
124. Gamier A, Fortin D, Delomenie C, Momken I, Veksler V, and Ventura-Clapier R. Depressed mitochondrial transcription factors and oxidative capacity in rat failing cardiac and skeletal muscles. J Physiol 551: 491-501, 2003.
125. Gertz EW, Wisneski JA, Neese R, Bristow JD, Searle GL, and Hanlon JT. Myocardial lactate metabolism: evidence of lactate release during net chemical extraction in man. Circulation 63: 1273-1279, 1981.
126. Gertz EW, Wisneski JA, Stanley WC, and Neese RA. Myocardial substrate utilization during exercise in humans. Dual carbon-labeled carbohydrate isotope experiments. J Clin Invest 82: 2017-2025, 1988.
127. Gibala MJ, Young ME, and Taegtmeyer H. Anaplerosis of the citric acid cycle: role in energy metabolism of heart and skeletal muscle. Acta Physiol Scand 168: 657-665, 2000.
128. Gibbs CL. Cardiac energetics. Physiol Rev 58: 174-254, 1978.
129. Gilde AJ, Van Der Lee KA, Willemsen PH, Chinetti G, Van Der Leij FR, van der Vusse GJ, Staels B, and van Bilsen M. Peroxisome proliferator-activated receptor (PPAR) α and PPARβ/δ, but not PPARγ, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res 92: 518-524, 2003.
130. Girard J, Ferre P, Pegorier JP, and Duee PH. Adaptations of glucose and fatty acid metabolism during perinatal period and suckling-weaning transition. Physiol Rev 72: 507-562, 1992.
131. Glatz JF, Luiken JJ, and Bonen A. Involvement of membrane-associated proteins in the acute regulation of cellular fatty acid uptake. J Mol Neurosci 16: 123-132, 2001.
132. Glatz JF and Veerkamp JH. Postnatal development of palmitate oxidation and mitochondrial enzyme activities in rat cardiac and skeletal muscle. Biochim Biophys Acta 711: 327-335, 1982.
133. Goldfarb AH, Bruno JF, and Buckenmeyer PJ. Intensity and duration effects of exercise on heart cAMP, phosphorylase, and glycogen. J Appl Physiol 60: 1268-1273, 1986.
134. Gollob MH. Glycogen storage disease as a unifying mechanism of disease in the PRKAG2 cardiac syndrome. Biochem Soc Trans 31: 228-231, 2003.
135. Gollob MH, Seger JJ, Gollob TN, Tapscott T, Gonzales O, Bachinski L, and Roberts R. Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy. Circulation 104: 3030-3033, 2001.
136. Gong G, Liu J, Liang P, Guo T, Hu Q, Ochiai K, Hou M, Ye Y, Wu X, Mansoor A, From AH, Ugurbil K, Bache RJ, and Zhang J. Oxidative capacity in failing hearts. Am J Physiol Heart Circ Physiol 285: H541-H548, 2003.
137. Goodwin GW and Taegtmeyer H. Regulation of fatty acid oxidation of the heart by MCD and ACC during contractile stimulation. Am J Physiol Endocrinol Metab 277: E772-E777, 1999.
138. Goodwin GW and Taegtmeyer H. Improved energy homeostasis of the heart in the metabolic state of exercise. Am J Physiol Heart Circ Physiol 279: H1490-H1501, 2000.
139. Goodwin GW, Taylor CS, and Taegtmeyer H. Regulation of energy metabolism of the heart during acute increase in heart work. J Biol Chem 273: 29530-29539, 1998.
140. Goulston A. The beneficial effect of ingestion of cane sugar in certain forms of heart disease. Br J Med i: 615, 1911.
141. Guth BD, Wisneski JA, Neese RA, White FC, Heusch G, Mazer CD, and Gertz EW. Myocardial lactate release during ischemia in swine. Relation to regional blood flow. Circulation 81: 1948-1958, 1990.
142. Hacker TA, Renstrom B, Paulson D, Liedtke AJ, and Stanley WC. Ischemia produces an increase in ammonia output in swine myocardium. Cardioscience 5: 255-260, 1994.
143. Hall JL, Lopaschuk GD, Barr A, Bringas J, Pizzurro RD, and Stanley WC. Increased cardiac fatty acid uptake with dobutamine infusion in swine is accompanied by a decrease in malonyl CoA levels. Cardiovasc Res 32: 879-885, 1996.
144. Hall JL, Mazzeo RS, Podolin DA, Cartee GD, and Stanley WC. Exercise training does not compensate for age-related decrease in myocardial GLUT-4 content. J Appl Physiol 76: 328-332, 1994.
145. Hall JL, Stanley WC, Lopaschuk GD, Wisneski JA, Pizzurro RD, Hamilton CD, and McCormack JG. Impaired pyruvate oxidation but normal glucose uptake in diabetic pig heart during dobutamine-induced work. Am J Physiol Heart Circ Physiol 271: H2320-H2329, 1996.
146. Hamilton C and Saggerson ED. Malonyl-CoA metabolism in cardiac myocytes. Biochem J 350: 61-67, 2000.
147. Hansford RG and Castro F. Age-linked changes in the activity of enzymes of the tricarboxylate cycle and lipid oxidation, and of carnitine content, in muscles of the rat. Mech Ageing Dev 19: 191-200, 1982.
148. Hansford RG and Cohen L. Relative importance of pyruvate dehydrogenase interconversion and feed-back inhibition in the effect of fatty acids on pyruvate oxidation by rat heart mitochondria. Arch Biochem Biophys 191: 65-81, 1978.
149. Hansson A, Hance N, Dufour E, Rantanen A, Hultenby K, Clayton DA, Wibom R, and Larsson NG. A switch in metabolism precedes increased mitochondrial biogenesis in respiratory chain-deficient mouse hearts. Proc Natl Acad Sci USA 101: 3136-3141, 2004.
150. Harris RA, Huang B, and Wu P. Control of pyruvate dehydrogenase kinase gene expression. Adv Enzyme Regul 41: 269-288, 2001.
151. Hasenfuss G, Maier LS, Hermann HP, Luers C, Hunlich M, Zeitz O, Janssen PM, and Pieske B. Influence of pyruvate on contractile performance and Ca(2+) cycling in isolated failing human myocardium. Circulation 105: 194-199, 2002.
152. Hasselbaink DM, Glatz JT, Luiken JJ, Roemen TH, and van der Vusse GJ. Ketone bodies disturb fatty acid handling in isolated cardiomyocytes derived from control and diabetic rats. Biochem J 371: 753-760, 2003.
153. Heineman FW and Balaban RS. Control of mitochondrial respiration in the heart in vivo. Annu Rev Physiol 52: 523-542, 1990.
154. Helmer GA, McKirnan MD, Shabetai R, Boss GR, Ross J Jr, and Hammond HK. Regional deficits of myocardial blood flow and function in left ventricular pacing-induced heart failure. Circulation 94: 2260-2267, 1996.
155. Henning SL, Wambolt RB, Schonekess BO, Lopaschuk GD, and Allard MF. Contribution of glycogen to aerobic myocardial glucose utilization. Circulation 93: 1549-1555, 1996.
156. Henry CG, Strauss AW, Keating JP, and Hillman RE. Congestive cardiomyopathy associated with beta-ketothiolase deficiency. J Pediatr 99: 754-757, 1981.
157. Hermann HP. Energetic stimulation of the heart. Cardiovasc Drugs Ther 15: 405-411, 2001.
158. Hermann HP, Arp J, Pieske B, Kogler H, Baron S, Janssen PM, and Hasenfuss G. Improved systolic and diastolic myocardial function with intracoronary pyruvate in patients with congestive heart failure. Eur J Heart Fail 6: 213-218, 2004.
159. Hermann HP, Pieske B, Schwarzmuller E, Keul J, Just H, and Hasenfuss G. Haemodynamic effects of intracoronary pyruvate in patients with congestive heart failure: an open study. Lancet 353: 1321-1323, 1999.
160. Hermann HP, Zeitz O, Keweloh B, Hasenfuss G, and Janssen PM. Pyruvate potentiates inotropic effects of isoproterenol and Ca(2+) in rabbit cardiac muscle preparations. Am J Physiol Heart Circ Physiol 279: H702-H708, 2000.
161. Hermann HP, Zeitz O, Lehnart SE, Keweloh B, Datz N, Hasenfuss G, and Janssen PM. Potentiation of beta-adrenergic inotropic response by pyruvate in failing human myocardium. Cardiovasc Res 53: 116-123, 2002.
162. Hickson-Bick DL, Buja ML, and McMillin JB. Palmitate-mediated alterations in the fatty acid metabolism of rat neonatal cardiac myocytes. J Mol Cell Cardiol 32: 511-519, 2000.
163. Higgins AJ, Faccini JM, and Greaves P. Coronary hyperemia and cardiac hypertrophy following inhibition of fatty acid oxidation. Evidence of a regulatory role for cytosolic phosphorylation potential. Adv Myocardiol 6: 329-338, 1985.
164. Higgins AJ, Morville M, Burges RA, and Blackburn KJ. Mechanism of action of oxfenicine on muscle metabolism. Biochem Biophys Res Commun 100: 291-296, 1981.
165. Higgins AJ, Morville M, Burges RA, Gardiner DG, Page MG, and Blackburn KJ. Oxfenicine diverts rat muscle metabolism from fatty acid to carbohydrate oxidation and protects the ischaemic rat heart. Life Sci 27: 963-970, 1980.
166. Himms-Hagen J and Harper ME. Physiological role of UCP3 may be export of fatty acids from mitochondria when fatty acid oxidation predominates: an hypothesis. Exp Biol Med 226: 78-84, 2001.
167. Hittinger L, Shannon RP, Bishop SP, Gelpi RJ, and Vatner SF. Subendomyocardial exhaustion of blood flow reserve and increased fibrosis in conscious dogs with heart failure. Circ Res 65: 971-980, 1989.
168. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vitovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, Janosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, and Deedwania P. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 283: 1295-1302, 2000.
169. Hoerter JA and Opie LH. Perinatal changes in glycolytic function in response to hypoxia in the incubated or perfused rat heart. Biol Neonate 33: 144-161, 1978.
170. Hoppel CL, Tandler B, Parland W, Turkaly JS, and Albers LD. Hamster cardiomyopathy. A defect in oxidative phosphorylation in the cardiac interflbrillar mitochondria. J Biol Chem 257: 1540-1548, 1982.
171. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Woo MA, and Tillisch JH. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol 38: 789-795, 2001.
172. Huang B, Wu P, Bowker-Kinley MM, and Harris RA. Regulation of pyruvate dehydrogenase kinase expression by peroxisome proliferator-activated receptor-alpha ligands, glucocorticoids, and insulin. Diabetes 51: 276-283, 2002.
173. Huang JM, Xian H, and Bacaner M. Long-chain fatty acids activate calcium channels in ventricular myocytes. Proc Natl Acad Sci USA 89: 6452-6456, 1992.
174. Hubert HB, Feinleib M, McNamara PM, and Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 67: 968-977, 1983.
175. Hue L, Beauloye C, Bertrand L, Herman S, Krause U, Marsin AS, Meisse D, Vertommen D, and Rider MH. New targets of AMP-activated protein kinase. Biochem Soc Trans 31: 213-215, 2003.
176. Hue L, Depre C, Lefebvre V, Rider MH, and Veitch K. Regulation of glucose metabolism in cardiac muscle. Biochem Soc Trans 23: 311-314, 1995.
177. Hue L and Rider MH. Role of fructose 2,6-bisphosphate in the control of glycolysis in mammalian tissues. Biochem J 245: 313-324, 1987.
178. Hunt MC and Alexson SE. The role Acyl-CoA thioesterases play in mediating intracellular lipid metabolism. Prog Lipid Res 41: 99-130, 2002.
179. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldmanmd AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Jacobs AK, Hiratzka LF, Russell RO, and Smith SC Jr. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation 104: 2996-3007, 2001.
180. Huss JM and Kelly DP. Nuclear receptor signaling and cardiac energetics. Circ Res 95: 568-578, 2004.
181. Huss JM, Kopp RP, and Kelly DP. Peroxisome proliferator-activated receptor coactivator-1alpha (PGC-1alpha) coactivates the cardiac-enriched nuclear receptors estrogen-related receptor-alpha and -gamma. Identification of novel leucine-rich interaction motif within PGC-1alpha. J Biol Chem 277: 40265-40274, 2002.
182. Huss JM, Torra IP, Staels B, Giguere V, and Kelly DP. Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. Mol Cell Biol 24: 9079-9091, 2004.
183. Hutter JF, Schweickhardt C, Piper HM, and Spieckermann PG. Inhibition of fatty acid oxidation and decrease of oxygen consumption of working rat heart by 4-bromocrotonic acid. J Mol Cell Cardiol 16: 105-108, 1984.
184. Ide T, Tsutsui H, Kinugawa S, Utsumi H, Rang D, Hattori N, Uchida K, Arimura K, Egashira K, and Takeshita A. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 85: 357-363, 1999.
185. Idell-Wenger JA, Grotyohann LW, and Neely JR. Coenzyme A and carnitine distribution in normal and ischemic hearts. J Biol Chem 253: 4310-4318, 1978.
186. Iemitsu M, Miyauchi T, Maeda S, Tanabe T, Takanashi M, Irukayama-Tomobe Y, Sakai S, Ohmori H, Matsuda M, and Yamaguchi I. Aging-induced decrease in the PPAR-alpha level in hearts is improved by exercise training. Am J Physiol Heart Circ Physiol 283: H1750-H1760, 2002.
187. Iliceto S, Scrutinio D, Bruzzi P, D'Ambrosio G, Boni L, Di Biase M, Biasco G, Hugenholtz PG, and Rizzon P. Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografla Digitalizzata Infarto Miocardico (CEDIM) Trial. J Am Coll Cardiol 26: 380-387, 1995.
188. Ingwall JS. ATP and the Heart. Boston, MA: Kluwer, 2001.
189. Ingwall JS. Transgenesis and cardiac energetics: new insights into cardiac metabolism. J Mol Cell Cardiol 37: 613-623, 2004.
190. Ingwall JS and Weiss RG. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res 95: 135-145, 2004.
191. Ishiyama T, Morita Y, Toyama S, Yamagami T, and Tsukamoto N. A clinical study of the effect of coenzyme Q on congestive heart failure. Jpn Heart J 17: 32-42, 1976.
192. Itoi T and Lopaschuk GD. The contribution of glycolysis, glucose oxidation, lactate oxidation, and fatty acid oxidation to ATP production in isolated biventricular working hearts from 2-week-old rabbits. Pediatr Res 34: 735-741, 1993.
193. Jaburek M, Varecha M, Jezek P, and Garlid KD. Alkylsulfonates as probes of uncoupling protein transport mechanism. Ion pair transport demonstrates that direct H(+) translocation by UCP1 is not necessary for uncoupling. J Biol Chem 276: 31897-31905, 2001.
194. Jagasia D, Whiting JM, Concato J, Pfau S, and McNulty PH. Effect of non-insulin-dependent diabetes mellitus on myocardial insulin responsiveness in patients with ischemic heart disease. Circulation 103: 1734-1739, 2001.
195. Jain D, Dasgupta P, Hughes LO, Lahiri A, and Raftery EB. Ranolazine (RS-43285): a preliminary study of a new anti-anginal agent with selective effect on ischaemic myocardium. Eur J Clin Pharmacol 38: 111-114, 1990.
196. Jarreta D, Orus J, Barrientos A, Miro O, Roig E, Heras M, Moraes CT, Cardellach F, and Casademont J. Mitochondrial function in heart muscle from patients with idiopathic dilated cardiomyopathy. Cardiovasc Res 45: 860-865, 2000.
197. Jeremy RW, Koretsune Y, Marban E, and Becker LC. Relation between glycolysis and calcium homeostasis in postischemic myocardium. Circ Res 70: 1180-1190, 1992.
198. Jezek P, Engstova H, Zackova M, Vercesi AE, Costa AD, Arruda P, and Garlid KD. Fatty acid cycling mechanism and mitochondrial uncoupling proteins. Biochim Biophys Acta 1365: 319-327, 1998.
199. Jezek P, Engstova H, Zackova M, Vercesi AE, Costa AD, Arruda P, and Garlid KD. Fatty acid cycling mechanism and mitochondrial uncoupling proteins. Biochim Biophys Acta 1365: 319-327, 1998.
200. Jezek P, Modriansky M, and Garlid KD. A structure-activity study of fatty acid interaction with mitochondrial uncoupling protein. FEES Lett 408: 166-170, 1997.
201. Jezek P, Modriansky M, and Garlid KD. Inactive fatty acids are unable to flip-flop across the lipid bilayer. FEES Lett 408: 161-165, 1997.
202. Johannsson E, Lunde PK, Heddle C, Sjaastad I, Thomas MJ, Bergersen L, Halestrap AP, Blackstad TW, Ottersen OP, and Sejersted OM. Upregulation of the cardiac monocarboxylate transporter MCT1 in a rat model of congestive heart failure. Circulation 104: 729-734, 2001.
203. Johannsson E, Nagelhus EA, McCullagh KJ, Sejersted OM, Blackstad TW, Bonen A, and Ottersen OP. Cellular and subcellular expression of the monocarboxylate transporter MCT1 in rat heart. A high-resolution immunogold analysis. Circ Res 80: 400-407, 1997.
204. Kaijser L and Berglund B. Myocardial lactate extraction and release at rest and during heavy exercise in healthy men. Acta Physiol Scand 144: 39-45, 1992.
205. Kako KJ, Thornton MJ, and Heggtveit HA. Depressed fatty acid and acetate oxidation and other metabolic defects in homogenates from hearts of hamsters with hereditary cardiomyopathy. Circ Res 34: 570-580, 1974.
206. Kalsi KK, Smolenski RT, Pritchard RD, Khaghani A, Seymour AM, and Yacoub MH. Energetics and function of the failing human heart with dilated or hypertrophic cardiomyopathy. Eur J Clin Invest 29: 469-477, 1999.
207. Kantor PF, Lucien A, Kozak R, and Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 86: 580-588, 2000.
208. Kantor PF, Robertson MA, Coe JY, and Lopaschuk GD. Volume overload hypertrophy of the newborn heart slows the maturation of enzymes involved in the regulation of fatty acid metabolism. J Am Coll Cardiol 33: 1724-1734, 1999.
209. Kantor PFLGDOLH. Myocardial energy metabolism. In: Heart Physiology and Pathophysiology, edited by Opie LH. Orlando, FL: Academic, 2004, p. 543-569.
210. Karbowska J, Kochan Z, and Smolenski RT. Peroxisome proliferator- activated receptor alpha is downregulated in the failing human heart. Cell Mol Biol Lett 8: 49-53, 2003.
211. Kates AM, Herrero P, Dence C, Soto P, Srinivasan M, Delano DG, Ehsani A, and Gropler RJ. Impact of aging on substrate metabolism by the human heart. J Am Coll Cardiol 41: 293-299, 2003.
212. Katz AM. Energetics and the failing heart. Hosp Pract 26: 78-90, 1991.
213. Katz AM. Metabolism of the failing heart. Cardioscience 4: 199-203, 1993.
214. Katz AM and Katz PB. Diseases of the heart in the works of Hippocrates. Br Heart J 24: 257-264, 1962.
215. Katz AM. Heart Failure: Pathophysiology, Molecular Biology, and Clinical Management. Philadelphia, PA: Lippincott Williams & Wilkins, 2000.
216. Kelly DP. PPARs of the heart: three is a crowd. Circ Res 92: 482-484, 2003.
217. Kelly DP and Strauss AW. Inherited cardiomyopathies. N Engl J Med 330: 913-919, 1994.
218. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB, and Vasan RS. Obesity and the risk of heart failure. N Engl J Med 347: 305-313, 2002.
219. Kerbey AL, Randle PJ, Cooper RH, Whitehouse S, Pask HT, and Denton RM. Regulation of pyruvate dehydrogenase in rat heart. Mechanism of regulation of proportions of dephosphorylated and phosphorylated enzyme by oxidation of fatty acids and ketone bodies and of effects of diabetes: role of coenzyme A, acetylcoenzyme A and reduced and oxidized nicotinamide-adenine dinucleotide. Biochem J 154: 327-348, 1976.
220. Kerner J and Hoppel C. Fatty acid import into mitochondria. Biochim Biophys Acta 1486: 1-17, 2000.
221. Kerner J and Hoppel CL. Radiochemical malonyl-CoA decarboxylase assay: activity and subcellular distribution in heart and skeletal muscle. Anal Biochem 306: 283-289, 2002.
222. Kerner J, Turkaly PJ, Minkler PE, and Hoppel CL. Aging skeletal muscle mitochondria in the rat: decreased uncoupling protein-3 content. Am J Physiol Endocrinol Metab 281: E1054-E1062, 2001.
223. Kerner J, Zaluzec E, Gage D, and Bieber LL. Characterization of the malonyl-CoA-sensitive carnitine palmitoyltransferase (CPTo) of a rat heart mitochondrial particle. Evidence that the catalytic unit is CPTi. J Biol Chem 269: 8209-8219, 1994.
224. 13C-substrates: focusing on the origin and fate of pyruvate and citrate carbons. Am J Physiol Heart Circ Physiol 286: H1461-H1470, 2004.
225. Kim YS and Kolattukudy PE. Purification and properties of malonyl-CoA decarboxylase from rat liver mitochondria and its immunological comparison with the enzymes from rat brain, heart, and mammary gland. Arch Biochem Biophys 190: 234-246, 1978.
226. Kintaka T, Tanaka T, Imai M, Adachi I, Narabayashi I, and Kitaura Y. CD36 genotype and long-chain fatty acid uptake in the heart. Circ J 66: 819-825, 2002.
227. Kjekshus JK and Mjos OD. Effect of free fatty acids on myocardial function and metabolism in the ischemic dog heart. J Clin Invest 51: 1767-1776, 1972.
228. Knapp FF Jr and Kropp J, BMIPP-design and development. Int J Card Imaging 15: 1-9, 1999.
229. Knuuti MJ, Maki M, Yki-Jarvinen H, Voipio-Pulkki LM, Harkonen R, Haaparanta M, and Nuutila P. The effect of insulin and FFA on myocardial glucose uptake. J Mol Cell Cardiol 27: 1359-1367, 1995.
230. Knuuti MJ, Yki-Jarvinen H, Voipio-Pulkki LM, Maki M, Ruotsalainen U, Harkonen R, Teras M, Haaparanta M, Bergman J, AND Hartiala J. Enhancement of myocardial [fluorine-18]fluorodeoxyglucose uptake by a nicotinic acid derivative. J Nucl Med 35: 989-998, 1994.
231. Kornberg HL. Anaplerotic sequences and their role in metabolism. In: Essays in Biochemistry, edited by Campbell PN and Marshall RD. London: Academic, 1966, p. 1-31.
232. Korvald C, Elvenes OP, and Myrmel T. Myocardial substrate metabolism influences left ventricular energetics in vivo. Am J Physiol Heart Circ Physiol 278: H1345-H1351, 2000.
233. Kreisberg RA. Effect of epinephrine on myocardial triglyceride and free fatty acid utilization. Am J Physiol 210: 385-389, 1966.
234. Kropp J, Eisenhut M, Ambrose KR, Knapp FF Jr, and Franke WG. Pharmacokinetics and metabolism of the methyl-branched fatty acid (BMIPP) in animals and humans. J Nucl Med 40: 1484-1491, 1999.
235. Kruszynska YT, McCormack JG, and McIntyre N. Effects of glycogen stores and non-esterified fatty acid availability on insulin-stimulated glucose metabolism and tissue pyruvate dehydrogenase activity in the rat. Diabetologia 34: 205-211, 1991.
236. Kudo N, Barr AJ, Barr RL, Desai S, and Lopaschuk GD. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem 270: 17513-17520, 1995.
237. Kudo T, Fukuchi K, Annala AJ, Chatziioannou AF, Allada V, Dahlbom M, Tai YC, Inubushi M, Huang SC, Cherry SR, Phelps ME, and Schelbert HR. Noninvasive measurement of myocardial activity concentrations and perfusion defect sizes in rats with a new small-animal positron emission tomograph. Circulation 106: 118-123, 2002.
238. Kunau WH, Dommes V, and Schulz H. Beta-oxidation of fatty acids in mitochondria, peroxisomes, and bacteria: a century of continued progress. Prog Lipid Res 34: 267-342, 1995.
239. Kurzelewski M, Duda M, Stanley WC, Boemke W, and Beresewicz A. Nitric oxide synthase inhibition and elevated endothelin increase oxygen consumption but do not affect glucose and palmitate oxidation in the isolated rat heart. J Physiol Pharmacol 55: 27-38, 2004.
240. 2+ homeostasis in ferret myocardium? J Clin Invest 93: 1216-1223, 1994.
241. Lakatta EG. Cardiovascular aging: perspectives from humans to rodents. Am J Geriatr Cardiol 7: 32-45, 1998.
242. Lakatta EG. Age-associated cardiovascular changes in health: impact on cardiovascular disease in older persons. Heart Fail Rev 7: 29-49, 2002.
243. Lammerant J, Huynh-Thu T, and Kolanowski J. Inhibitory effects of the D(-)isomer of 3-hydroxybutyrate on cardiac non-esterified fatty acid uptake and oxygen demand induced by norepinephrine in the intact dog. J Mol Cell Cardiol 17: 421-433, 1985.
244. 13C mass isotopomer study. Am J Physiol Endocrinol Metab 272: E74-E82, 1997.
245. Lassers BW, Wahlqvist ML, Kaijser L, and Carlson LA. Effect of nicotinic acid on myocardial metabolism in man at rest and during exercise. J Appl Physiol 33: 72-80, 1972.
246. Laughlin MR, Taylor J, Chesnick AS, and Balaban RS. Non-glucose substrates increase glycogen synthesis in vivo in dog heart. Am J Physiol Heart Circ Physiol 267: H219-H223, 1994.
247. Lavie CJ and Milani RV. Obesity and cardiovascular disease: the hippocrates paradox? J Am Coll Cardiol 42: 677-679, 2003.
248. Lavie CJ, Osman AF, Milani RV, and Mehra MR. Body composition and prognosis in chronic systolic heart failure: the obesity paradox. Am J Cardiol 91: 891-894, 2003.
249. Lawson JW and Uyeda K. Effects of insulin and work on fructose 2,6-bisphosphate content and phosphofructokinase activity in perfused rat hearts. J Biol Chem 262: 3165-3173, 1987.
250. Lehman JJ, Barger PM, Kovacs A, Saffitz JE, Medeiros DM, and Kelly DP. Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest 106: 847-856, 2000.
251. Lehman JJ and Kelly DP. Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth. Heart Fail Rev 7: 175-185, 2002.
252. Lei B, Lionetti V, Young ME, Chandler MP, D' Agostino C, Rang E, Altarejos M, Matsuo K, Hintze TH, Stanley WC, and Recchia FA. Paradoxical downregulation of the glucose oxidation pathway despite enhanced flux in severe heart failure. J Mol Cell Cardiol 36: 567-576, 2004.
253. Lesnefsky EJ, Moghaddas S, Tandler B, Kerner J, and Hoppel CL. Mitochondrial dysfunction in cardiac disease: ischemia-reperfusion, aging, and heart failure. J Mol Cell Cardiol 33: 1065-1089, 2001.
254. Lewandowski ED. Metabolic mechanisms associated with antianginal therapy. Circ Res 86: 487-489, 2000.
255. Li J, Hu X, Selvakumar P, Russell RR, III, Cushman SW, Holman GD, and Young LH. Role of the nitric oxide pathway in AMPK-mediated glucose uptake and GLUT4 translocation in heart muscle. Am J Physiol Endocrinol Metab 287: E834-E841, 2004.
256. Liao R, Jain M, Cui L, D'Agostino J, Aiello F, Luptak I, Ngoy S, Mortensen RM, and Tian R. Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation 106: 2125-2131, 2002.
257. Liao R, Nascimben L, Friedrich J, Gwathmey JK, and Ingwall JS. Decreased energy reserve in an animal model of dilated cardiomyopathy. Relationship to contractile performance. Circ Res 78: 893-902, 1996.
258. Liedtke AJ, Hacker T, Renstrom B, and Nellis SH. Anaplerotic effects of propionate on oxidations of acetate and long-chain fatty acids. Am J Physiol Heart Circ Physiol 270: H2197-H2203, 1996.
259. Lionetti V, Linke A, Chandler MP, Young ME, Penn MS, Gupte S, d'Agostino C, Hintze TH, Stanley WC, and Recchia FA. Carnitine palmitoyl transferase-I inhibition prevents ventricular remodeling and delays decompensation in pacing-induced heart failure. Cardiovasc Res 66: 274-281, 2005.
260. Listenberger LL, Ory DS, and Schaffer JE. Palmitate-induced apoptosis can occur through a ceramide-independent pathway. J Biol Chem 276: 14890-14895, 2001.
261. Little JR, Goto M, and Spitzer JJ. Effect of ketones on metabolism of FFA by dog myocardium and skeletal muscle in vivo. Am J Physiol 219: 1458-1463, 1970.
262. Liu J, Wang C, Murakami Y, Gong G, Ishibashi Y, Prody C, Ochiai K, Bache RJ, Godinot C, and Zhang J. Mitochondrial ATPase and high-energy phosphates in failing hearts. Am J Physiol Heart Circ Physiol 281: H1319-H1326, 2001.
263. Liu YH, Yang XP, Nass O, Sabbah HN, Peterson E, and Carretero OA. Chronic heart failure induced by coronary artery ligation in Lewis inbred rats. Am J Physiol Heart Circ Physiol 272: H722-H727, 1997.
264. Lommi J, Koskinen P, Naveri H, Harkonen M, and Kupari M. Heart failure ketosis. J Intern Med 242: 231-238, 1997.
265. Lommi J, Kupari M, Koskinen P, Naveri H, Leinonen H, Pulkki K, and Harkonen M. Blood ketone bodies in congestive heart failure. J Am Coll Cardiol 28: 665-672, 1996.
266. Lommi J, Kupari M, and Yki-Jarvinen H. Free fatty acid kinetics and oxidation in congestive heart failure. Am J Cardiol 81: 45-50, 1998.
267. Longnus SL, Wambolt RB, Parsons HL, Brownsey RW, and Allard MF. 5-Aminoimidazole-4-carboxamide 1-beta-D-ribofuranoside (AICAR) stimulates myocardial glycogenolysis by allosteric mechanisms. Am J Physiol Regul Integr Comp Physiol 284: R936-R944, 2003.
268. Lopaschuk GD, Barr R, Thomas PD, and Dyck JR. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Circ Res 93: e33-e37, 2003.
269. Lopaschuk GD and Barr RL. Measurements of fatty acid and carbohydrate metabolism in the isolated working rat heart. Mol Cell Biochem 172: 137-147, 1997.
270. Lopaschuk GD, Belke DD, Gamble J, Itoi T, and Schonekess BO. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta 1213: 263-276, 1994.
271. Lopaschuk GD, Collins-Nakai R, Olley PM, Montague TJ, McNeil G, Gayle M, Penkoske P, and Finegan BA. Plasma fatty acid levels in infants and adults after myocardial ischemia. Am Heart J 128: 61-67, 1994.
272. Lopaschuk GD, Collins-Nakai RL, and Itoi T. Developmental changes in energy substrate use by the heart. Cardiovasc Res 26: 1172-1180, 1992.
273. Lopaschuk GD and Spafford MA. Energy substrate utilization by isolated working hearts from newborn rabbits. Am J Physiol Heart Circ Physiol 258: H1274-H1280, 1990.
274. Lopaschuk GD, Spafford MA, and Marsh DR. Glycolysis is predominant source of myocardial ATP production immediately after birth. Am J Physiol Heart Circ Physiol 261: H1698-H1705, 1991.
275. Lopaschuk GD, Witters LA, Itoi T, Barr R, and Barr A. Acetyl-CoA carboxylase involvement in the rapid maturation of fatty acid oxidation in the newborn rabbit heart. J Biol Chem 269: 25871-25878, 1994.
276. Lucas DT and Szweda LI. Declines in mitochondrial respiration during cardiac reperfusion: age-dependent inactivation of alpha-ketoglutarate dehydrogenase. Proc Natl Acad Sci USA 96: 6689-6693, 1999.
277. Luiken JJ, Coort SL, Koonen DP, Van Der Horst DJ, Bonen A, Zorzano A, and Glatz JF. Regulation of cardiac long-chain fatty acid and glucose uptake by translocation of substrate transporters. Pflügers Arch 448: 1-15, 2004.
278. Luiken JJ, Coort SL, Wlllems J, Coumans WA, Bonen A, van der Vusse GJ, and Glatz JF. Contraction-induced fatty acid translocase/CD36 translocation in rat cardiac myocytes is mediated through AMP-activated protein kinase signaling. Diabetes 52: 1627-1634, 2003.
279. Luiken JJ, Willems J, van der Vusse GJ, and Glatz JF. Electrostimulation enhances FAT/CD36-mediated long-chain fatty acid uptake by isolated rat cardiac myocytes. Am J Physiol Endocrinol Metab 281: E704-E712, 2001.
280. Lygate CA, Hulbert K, Monfared M, Cole MA, Clarke K, and Neubauer S. The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. Cardiovasc Res 58: 632-637, 2003.
281. Lysiak W, Toth PP, Suelter CH, and Bieber LL. Quantitation of the efflux of acylcarnitines from rat heart, brain, and liver mitochondria. J Biol Chem 261: 13698-13703, 1986.
282. Makinde AO, Gamble J, and Lopaschuk GD. Upregulation of 5′-AMP-activated protein kinase is responsible for the increase in myocardial fatty acid oxidation rates following birth in the newborn rabbit. Circ Res 80: 482-489, 1997.
283. Mallet RT. Pyruvate: metabolic protector of cardiac performance. Proc Soc Exp Biol Med 223: 136-148, 2000.
284. 13C NMR spectroscopy. J Biol Chem 263: 6964-6971, 1988.
285. Marin-Garcia J and Goldenthal MJ. Fatty acid metabolism in cardiac failure: biochemical, genetic and cellular analysis. Cardiovasc Res 54: 516-527, 2002.
286. Marin-Garcia J, Goldenthal MJ, and Moe GW. Abnormal cardiac and skeletal muscle mitochondrial function in pacing-induced cardiac failure. Cardiovasc Res 52: 103-110, 2001.
287. Marin-Garcia J, Goldenthal MJ, and Moe GW. Mitochondrial pathology in cardiac failure. Cardiovasc Res 49: 17-26, 2001.
288. Marsin AS, Bertrand L, Rider MH, Deprez J, Beauloye C, Vincent MF, Van den BG, Carling D, and Hue L. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr Biol 10: 1247-1255, 2000.
289. Martin MA, Gomez MA, Guillen F, Bornstein B, Campos Y, Rubio JC, de la Calzada CS, and Arenas J. Myocardial carnitine and carnitine palmitoyltransferase deficiencies in patients with severe heart failure. Biochim Biophys Acta 1502: 330-336, 2000.
290. Martini WZ, Stanley WC, Huang H, Rosiers CD, Hoppel CL, and Brunengraber H. Quantitative assessment of anaplerosis from propionate in pig heart in vivo. Am J Physiol Endocrinol Metab 284: E351-E356, 2003.
291. Massie BM, Schaefer S, Garcia J, McKirnan MD, Schwartz GG, Wisneski JA, Weiner MW, and White FC. Myocardial high-energy phosphate and substrate metabolism in swine with moderate left ventricular hypertrophy. Circulation 91: 1814-1823, 1995.
292. Massie BM, Schwartz GG, Garcia J, Wisneski JA, Weiner MW, and Owens T. Myocardial metabolism during increased work states in the porcine left ventricle in vivo. Circ Res 74: 64-73, 1994.
293. Mazer CD, Stanley WC, Hickey RF, Neese RA, Cason BA, Demas KA, Wisneski JA, and Gertz EW. Myocardial metabolism during hypoxia: maintained lactate oxidation during increased glycolysis. Metabolism 39: 913-918, 1990.
294. 2+. Biochem J 218: 235-247, 1984.
295. McCormack JG and Denton RM. Influence of calcium ions on mammalian intramitochondrial dehydrogenases. Methods Enzymol 174: 95-118, 1989.
296. McCormack JG, Halestrap AP, and Denton RM. Role of calcium ions in regulation of mammalian intramitochondrial metabolism. Physiol Rev 70: 391-425, 1990.
297. McCormack JG, Stanley WC, and Wolff AA. Ranolazine: a novel metabolic modulator for the treatment of angina. Gen Pharmacol 30: 639-645, 1998.
298. McCutcheon LJ, Cory CR, Nowack L, Shen H, Mirsalami M, Lahucky R, Kovac L, O'Grady M, Horne R, and O'Brien PJ. Respiratory chain defect of myocardial mitochondria in idiopathic dilated cardiomyopathy of Doberman pinscher dogs. Can J Physiol Pharmacol 70: 1529-1533, 1992.
299. McDonald KM, Yoshiyama M, Francis GS, Ugurbil K, Cohn JN, and Zhang J. Myocardial bioenergetic abnormalities in a canine model of left ventricular dysfunction. J Am Coll Cardiol 23: 786-793, 1994.
300. McGarry JD and Brown NF. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem 244: 1-14, 1997.
301. McGarry JD and Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 42: 128-138, 1999.
302. McGarry JD, Mills SE, Long CS, and Foster DW. Observations on the affinity for carnitine, and malonyl-CoA sensitivity, of carnitine palmitoyltransferase I in animal and human tissues. Demonstration of the presence of malonyl-CoA in non-hepatic tissues of the rat. Biochem J 214: 21-28, 1983.
303. McMillin JB, Taffet GE, Taegtmeyer H, Hudson EK, and Tate CA. Mitochondrial metabolism and substrate competition in the aging Fischer rat heart. Cardiovasc Res 27: 2222-2228, 1993.
304. McMillin JB, Wang D, Witters LA, and Buja LM. Kinetic properties of carnitine palmitoyltransferase I in cultured neonatal rat cardiac myocytes. Arch Biochem Biophys 312: 375-384, 1994.
305. McNulty PH, Jacob R, Deckelbaum LI, and Young LH. Effect of hyperinsulinemia on myocardial amino acid uptake in patients with coronary artery disease. Metabolism 49: 1365-1369, 2000.
306. Merkel M, Eckel RH, and Goldberg IJ. Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res 43: 1997-2006, 2002.
307. Mirotsou M, Watanabe CM, Schultz PG, Pratt RE, and Dzau VJ. Elucidating the molecular mechanism of cardiac remodeling using a comparative genomic approach. Physiol Gen 15: 115-126, 2003.
308. 125I-iodophenyl 9-methylpentadecanoic acid (9MPA) and expression of fatty acid utilization enzymes in volume-overloaded hearts. Eur J Clin Invest 34: 176-181, 2004.
309. Mjos OD. Effect of free fatty acids on myocardial function and oxygen consumption in intact dogs. J Clin Invest 50: 1386-1389, 1971.
310. Mjos OD and Kjekshus J. Increased local metabolic rate by free fatty acids in the intact dog heart. Scand J Clin Lab Invest 28: 389-393, 1971.
311. Mjos OD, Kjekshus JK, and Lekven J. Importance of free fatty acids as a determinant of myocardial oxygen consumption and myocardial ischemic injury during norepinephrine infusion in dogs. J Clin Invest 53: 1290-1299, 1974.
312. Moe GW, Marin-Garcia J, Konig A, Goldenthal M, Lu X, and Feng Q. In vivo TNF-alpha inhibition ameliorates cardiac mitochondrial dysfunction, oxidative stress, and apoptosis in experimental heart failure. Am J Physiol Heart Circ Physiol 287: H1813-H1820, 2004.
313. Mohr S, Hallak H, de Boitte A, Lapetina EG, and Brune B. Nitric oxide-induced S-glutathionylation and inactivation of glyceraldehyde-3-phosphate dehydrogenase. J Biol Chem 274: 9427-9430, 1999.
314. Montgomery C, Hamilton N, and Ianuzzo CD. Energy status of the rapidly paced canine myocardium in congestive heart failure. J Appl Physiol 73: 2363-2367, 1992.
315. Mootha VK, Arai AE, and Balaban RS. Maximum oxidative phosphorylation capacity of the mammalian heart. Am J Physiol Heart Circ Physiol 272: H769-H775, 1997.
316. Mourmans J, Wendel U, Bentlage HA, Trijbels JM, Smeitink JA, de Coo IF, Gabreels FJ, Sengers RC, and Ruitenbeek W. Clinical heterogeneity in respiratory chain complex III deficiency in childhood. J Neurol Sci 149: 111-117, 1997.
317. Muders F and Elsner D. Animal models of chronic heart failure. Pharmacol Res 41: 605-612, 2000.
318. Mudge GH Jr, Mills RM Jr, Taegtmeyer H, Gorlin R, and Lesch M. Alterations of myocardial amino acid metabolism in chronic ischemic heart disease. J Clin Invest 58: 1185-1192, 1976.
319. Muoio DM, Seefeld K, Witters LA, and Coleman RA. AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: evidence that sn-glycerol-3-phosphate acyltransferase is a novel target. Biochem J 338: 783-791, 1999.
320. Neglia D, Michelassi C, Trivieri MG, Sambuceti G, Giorgetti A, Pratali L, Gallopin M, Salvadori P, Sorace O, Carpeggiani C, Poddighe R, L'Abbate A, and Parodi O. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation 105: 186-193, 2002.
321. Neglia D, Parodi O, Gallopin M, Sambuceti G, Giorgetti A, Pratali L, Salvadori P, Michelassi C, Lunardi M, and Pelosi G. Myocardial blood flow response to pacing tachycardia and to dipyridamole infusion in patients with dilated cardiomyopathy without overt heart failure. A quantitative assessment by positron emission tomography. Circulation 92: 796-804, 1995.
322. Neubauer S, Beer M, Landschutz W, Sandstede J, Seyfarth T, Lipke C, Kostler H, Pabst TW, Meininger M, von Kienlin M, Horn M, Harre K, and Hahn D. Absolute quantification of high energy phosphate metabolites in normal, hypertrophied and failing human myocardium. MAGMA 11: 73-74, 2000.
323. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS, and Kochsiek K. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 96: 2190-2196, 1997.
324. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered
325. Newsholme EA and Randle PJ. Regulation of glucose upake by muscle. Effects of fatty acids, ketone bodies and pyruvate, and of alloxan diabetes, starvation, hypophysectomy, and adrenalectomy, on the concentrations of hexose phosphates, nucleotides, and inorganic phosphate in perfused rat heart. Biochem J 93: 641-651, 1964.
326. Nikolaidis LA, Doverspike A, Hentosz T, Zourelias L, Shen YT, Elahi D, and Shannon RP. Glucagon-like peptide-1 (GLP-1) limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J Pharmacol Exp Ther 312: 303-308, 2005.
327. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, Stolarski C, Shen YT, and Shannon RP. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110: 955-961, 2004.
328. 2 utilization in heart failure. Cardiovasc Res 53: 392-404, 2002.
329. Nikolaidis LA, Sturzu A, Stolarski C, Elahi D, Shen YT, and Shannon RP. The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy. Cardiovasc Res 61: 297-306, 2004.
330. Oliveira SM, Ehtisham J, Redwood CS, Ostman-Smith I, Blair EM, and Watkins H. Mutation analysis of AMP-activated protein kinase subunits in inherited cardiomyopathies: implications for kinase function and disease pathogenesis. J Mol Cell Cardiol 35: 1251-1255, 2003.
331. Opie LH. The Heart: Physiology and Metabolism. New York: Raven, 1991.
332. Osorio JC, Stanley WC, Linke A, Castellari M, Diep QN, Panchal AR, Hintze TH, Lopaschuk GD, and Recchia FA. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation 106: 606-612, 2002.
333. Ostrander DB, Sparagna GC, Amoscato AA, McMillin JB, and Dowhan W. Decreased cardiolipin synthesis corresponds with cytochrome c release in palmitate-induced cardiomyocyte apoptosis. J Biol Chem 276: 38061-38067, 2001.
334. Ozcan C, Bienengraeber M, Hodgson DM, Mann DL, and Terzic A. Mitochondrial tolerance to stress impaired in failing heart. J Mol Cell Cardiol 35: 1161-1166, 2003.
335. Panchal AR, Comte B, Huang H, Dudar B, Roth B, Chandler M, des RC, Brunengraber H, and Stanley WC. Acute hibernation decreases myocardial pyruvate carboxylation and citrate release. Am J Physiol Heart Circ Physiol 281: H1613-H1620, 2001.
336. Panchal AR, Comte B, Huang H, Kerwin T, Darvish A, des Rosiers C, Brunengraber H, and Stanley WC. Partitioning of pyruvate between oxidation and anaplerosis in swine hearts. Am J Physiol Heart Circ Physiol 279: H2390-H2398, 2000.
337. Panchal AR, Stanley WC, Kerner J, and Sabbah HN. Beta-receptor blockade decreases carnitine palmitoyl transferase I activity in dogs with heart failure. J Card Fail 4: 121-126, 1998.
338. Paolisso G, Gambardella A, Galzerano D, D'Amore A, Rubino P, Verza M, Teasuro P, Varricchio M, and D'Onofrio F. Total-body and myocardial substrate oxidation in congestive heart failure. Metabolism 43: 174-179, 1994.
339. Paulson DJ, and Crass MF III. Endogenous triacylglycerol metabolism in diabetic heart. Am J Physiol Heart Circ Physiol 242: H1084-H1094, 1982.
340. Pepine CJ and Wolff AA. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group. Am J Cardiol 84: 46-50, 1999.
341. Peyton RB, Jones RN, Attarian D, Sink JD, Van Trigt P, Currie WD, and Wechsler AS. Depressed high-energy phosphate content in hypertrophied ventricles of animal and man: the biologic basis for increased sensitivity to ischemic injury. Ann Surg 196: 278-284, 1982.
342. Pfeffer JM, Pfeffer MA, Fletcher PJ, and Braunwald E. Ventricular performance in rats with myocardial infarction and failure. Am J Med 76: 99-103, 1984.
343. Pfeffer JM, Pfeffer MA, Fletcher PJ, and Braunwald E. Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol Heart Circ Physiol 260: H1406-H1414, 1991.
344. Pierce GN and Philipson KD. Binding of glycolytic enzymes to cardiac sarcolemmal and sarcoplasmic reticular membranes. J Biol Chem 260: 6862-6870, 1985.
345. Poirier M, Vincent G, Reszko AE, Bouchard B, Kelleher JK, Brunengraber H, and des Rosiers C. Probing the link between citrate and malonyl-CoA in perfused rat hearts. Am J Physiol Heart Circ Physiol 283: H1379-H1386, 2002.
346. Polekhina G, Gupta A, Michell BJ, van Denderen B, Murthy S, Feil SC, Jennings IG, Campbell DJ, Witters LA, Parker MW, Kemp BE, and Stapleton D. AMPK beta subunit targets metabolic stress sensing to glycogen. Curr Biol 13: 867-871, 2003.
347. Power JM and Tonkin AM. Large animal models of heart failure. Aust N Z J Med 29: 395-402, 1999.
348. Pressman BC and Lardy HA. Effects of surface active agents on the latent ATPase of mitochondria. Biochim Biophys Acta 21: 458-466, 1956.
349. Quigley AF, Kapsa RM, Esmore D, Hale G, and Byrne E. Mitochondrial respiratory chain activity in idiopathic dilated cardiomyopathy. J Card Fail 6: 47-55, 2000.
350. Randle PJ. Fuel selection in animals. Biochem Soc Trans 14: 799-806, 1986.
351. Randle PJ, Denton RM, and England PJ. Citrate as a metabolic regulator in muscle and adipose tissue. Biochem Soc Symp 27: 87-103, 1968.
352. Randle PJ, England PJ, and Denton RM. Control of the tricarboxylate cycle and its interactions with glycolysis during acetate utilization in rat heart. Biochem J 117: 677-695, 1970.
353. Randle PJ, Garland PB, Hales CN, and Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1: 785-789, 1963.
354. Randle PJ, Newsholme EA, and Garland PB. Regulation of glucose uptake by muscle. 8. Effects of fatty acids, ketone bodies and pyruvate, and of alloxan-diabetes and starvation, on the uptake and metabolic fate of glucose in rat heart and diaphragm muscles. Biochem J 93: 652-665, 1964.
355. Randle PJ and Priesman DA. Short term and longer term regulation of pyruvate dehydrogenase kinase. In: Alpha-keto Acid Dehydrogenase Complexes. Basel: Birkhauser Verlag, 1996, p. 151-161.
356. Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, and Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. Circulation 104: 2923-2931, 2001.
357. Razeghi P, Young ME, Ying J, Depre C, Uray IP, Kolesar J, Shipley GL, Moravec CS, Davies PJ, Frazier OH, and Taegtmeyer H. Downregulation of metabolic gene expression in failing human heart before and after mechanical unloading. Cardiology 97: 203-209, 2002.
358. Recchia FA. Role of nitric oxide in the regulation of substrate metabolism in heart failure. Heart Fail Rev 7: 141-148, 2002.
359. Recchia FA, McConnell PI, Bernstein RD, Vogel TR, Xu X, and Hintze TH. Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. Circ Res 83: 969-979, 1998.
360. Recchia FA, McConnell PI, Loke KE, Xu X, Ochoa M, and Hintze TH. Nitric oxide controls cardiac substrate utilization in the conscious dog. Cardiovasc Res 44: 325-332, 1999.
361. Recchia FA, Osorio JC, Chandler MP, Xu X, Panchal AR, Lopaschuk GD, Hintze TH, and Stanley WC. Reduced synthesis of NO causes marked alterations in myocardial substrate metabolism in conscious dogs. Am J Physiol Endocrinol Metab 282: E197-E206, 2002.
362. Remondino A, Rosenblatt-Velin N, Montessuit C, Tardy I, Papageorgiou I, Dorsaz PA, Jorge-Costa M, and Lerch R. Altered expression of proteins of metabolic regulation during remodeling of the left ventricle after myocardial infarction. J Mol Cell Cardiol 32: 2025-2034, 2000.
363. Renstrom B, Rommelfanger S, Stone CK, DeGrado TR, Carlson KJ, Scarbrough E, Nickles RJ, Liedtke AJ, and Holden JE. Comparison of fatty acid tracers FTHA and BMIPP during myocardial ischemia and hypoxia. J Nucl Med 39: 1684-1689, 1998.
364. 13C-isotopic enrichment of malonyl-coenzyme A by gas chromatography-mass spectrometry. Anal Biochem 298: 69-75, 2001.
365. Reszko AE, Kasumov T, David F, Jobbins KA, Thomas KR, Hoppel CL, Brunengraber H, and des Rosiers C. Peroxisomal fatty acid oxidation is a substantial source of the acetyl moiety of malonyl-CoA in rat heart. JBiol Chem 279: 19574-19579, 2004.
366. Reszko AE, Kasumov T, David F, Thomas KR, Jobbins KA, Cheng JF, Lopaschuk GD, Dyck JR, Diaz M, des Rosiers C, Stanley WC, and Brunengraber H. Regulation of malonyl-CoA concentration and turnover in the normal heart. J Biol Chem 279: 34298-34301, 2004.
367. Reszko AE, Kasumov T, Pierce BA, David F, Hoppel CL, Stanley WC, des Rosiers C, and Brunengraber H. Assessing the reversibility of the anaplerotic reactions of the propionyl-CoA pathway in heart and liver. J Biol Chem 278: 34959-34965, 2003.
368. Rider MH, Van Damme J, Vertommen D, Michel A, Vandekerckhove J, and Hue L. Evidence for new phosphorylation sites for protein kinase C and cyclic AMP-dependent protein kinase in bovine heart 6-phosphofructo-2-kinase/fructose- 2,6-bisphosphatase. FEBS Lett 310: 139-142, 1992.
369. Roe CR, Sweetman L, Roe DS, David F, and Brunengraber H. Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J Clin Invest 110: 259-269, 2002.
370. Rolfe DF, Hulbert AJ, and Brand MD. Characteristics of mitochondrial proton leak and control of oxidative phosphorylation in the major oxygen-consuming tissues of the rat. Biochim Biophys Acta 1188: 405-416, 1994.
371. Rolfe DF, Newman JM, Buckingham JA, Clark MG, and Brand MD. Contribution of mitochondrial proton leak to respiration rate in working skeletal muscle and liver and to SMR. Am J Physiol Cell Physiol 276: C692-C699, 1999.
372. Rolph TP and Jones CT. Regulation of glycolytic flux in the heart of the fetal guinea pig. J Dev Physiol 5: 31-49, 1983.
373. Rosano GM, Vitale C, Sposato B, Mercuro G, and Fini M. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diabetol 2: 16, 2003.
374. Rosenblatt-Velin N, Montessuit C, Papageorgiou I, Terrand J, and Lerch R. Postinfarction heart failure in rats is associated with upregulation of GLUT-1 and downregulation of genes of fatty acid metabolism. Cardiovasc Res 52: 407-416, 2001.
375. Ruderman NB, Saha AK, Vavvas D, and Witters LA. Malonyl-CoA, fuel sensing, and insulin resistance. Am J Physiol Endocrinol Metab 276: E1-E18, 1999.
376. Rupp H, Schulze W, and Vetter R. Dietary medium-chain triglycerides can prevent changes in myosin and SR due to CPT-1 inhibition by etomoxir. Am J Physiol Regul Integr Comp Physiol 269: R630-R640, 1995.
377. Rupp H and Vetter R. Sarcoplasmic reticulum function and carnitine palmitoyltransferase-1 inhibition during progression of heart failure. Br J Pharmacol 131: 1748-1756, 2000.
378. Rupp H, Zarain-Herzberg A, and Maisch B. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz 27: 621-636, 2002.
379. Russell RR, III, Bergeron R, Shulman GI, and Young LH. Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am J Physiol Heart Circ Physiol 277: H643-H649, 1999.
380. Russell RR III, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M, Giordano FJ, Mu J, Birnbaum MJ, and Young LH. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 114: 495-503, 2004.
381. Sabbah HH and Stanley WC. Partial fatty acid oxidation inhibitors: a potentially new class of drugs for heart failure. Eur J Heart Fail 4: 3-6, 2002.
382. Sabbah HN, Chandler MP, Mishima T, Suzuki G, Chaudhry P, Nass O, Biesiadecki BJ, Blackburn B, Wolff A, and Stanley WC. Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J Card Fail 8: 416-422, 2002.
383. Sabbah HN, Sharov V, Riddle JM, Kono T, Lesch M, and Goldstein S. Mitochondrial abnormalities in myocardium of dogs with chronic heart failure. J Mol Cell Cardiol 24: 1333-1347, 1992.
384. Sabbah HN, Shimoyama H, Kono T, Gupta RC, Sharov VG, Scicli G, Levine TB, and Goldstein S. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation 89: 2852-2859, 1994.
385. Sabbah HN, Stanley WC, Sharov VG, Mishima T, Tanimura M, Benedict CR, Hegde S, and Goldstein S. Effects of dopamine beta-hydroxylase inhibition with nepicastat on the progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Circulation 102: 1990-1995, 2000.
386. Sabbah HN, Stein PD, Kono T, Gheorghiade M, Levine TB, Jafri S, Hawkins ET, and Goldstein S. A canine model of chronic heart failure produced by multiple sequential coronary microembolizations. Am J Physiol Heart Circ Physiol 260: H1379-H1384, 1991.
387. Sacher HL, Sacher ML, Landau SW, Kersten R, Dooley F, Sacher A, Sacher M, Dietrick K, and Ichkhan K. The clinical and hemodynamic effects of coenzyme Q10 in congestive cardiomyopathy. Am J Ther 4: 66-72, 1997.
388. Sack MN and Kelly DP. The energy substrate switch during development of heart failure: gene regulatory mechanisms (review). Int J Mol Med 1: 17-24, 1998.
389. Sack MN, Rader TA, Park S, Bastin J, McCune SA, and Kelly DP. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 94: 2837-2842, 1996.
390. Saddik M, Gamble J, Witters LA, and Lopaschuk GD. Acetyl-CoA carboxylase regulation of fatty acid oxidation in the heart. J Biol Chem 268: 25836-25845, 1993.
391. Saddik M and Lopaschuk GD. Myocardial triglyceride turnover and contribution to energy substrate utilization in isolated working rat hearts. J Biol Chem 266: 8162-8170, 1991.
392. Saddik M and Lopaschuk GD. Myocardial triglyceride turnover during reperfusion of isolated rat hearts subjected to a transient period of global ischemia. J Biol Chem 267: 3825-3831, 1992.
393. Saddik M and Lopaschuk GD. Triacylglycerol turnover in isolated working hearts of acutely diabetic rats. Can J Physiol Pharmacol 72: 1110-1119, 1994.
394. Saha AK, Schwarsin AJ, Roduit R, Masse F, Kaushik V, Tornheim K, Prentki M, and Ruderman NB. Activation of malonyl-CoA decarboxylase in rat skeletal muscle by contraction and the AMP-activated protein kinase activator 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside. J Biol Chem 275: 24279-24283, 2000.
395. Saha AK, Vavvas D, Kurowski TG, Apazidis A, Witters LA, Shafrir E, and Ruderman NB. Malonyl-CoA regulation in skeletal muscle: its link to cell citrate and the glucose-fatty acid cycle. Am J Physiol Endocrinol Metab 272: E641-E648, 1997.
396. Sambandam N, Lopaschuk GD, Brownsey RW, and Allard MF. Energy metabolism in the hypertrophied heart. Heart Fail Rev 7: 161-173, 2002.
397. Sanbe A, Tanonaka K, Hanaoka Y, Katoh T, and Takeo S. Regional energy metabolism of failing hearts following myocardial infarction. J Mol Cell Cardiol 25: 995-1013, 1993.
398. Sanbe A, Tanonaka K, Kobayasi R, and Takeo S. Effects of long-term therapy with ACE inhibitors, captopril, enalapril and trandolapril, on myocardial energy metabolism in rats with heart failure following myocardial infarction. J Mol Cell Cardiol 27: 2209-2222, 1995.
399. Sanbe A, Tanonaka K, Niwano Y, and Takeo S. Improvement of cardiac function and myocardial energy metabolism of rats with chronic heart failure by long-term coenzyme Q10 treatment. J Pharmacol Exp Ther 269: 51-56, 1994.
400. Scarpulla RC. Nuclear activators and coactivators in mammalian mitochondrial biogenesis. Biochim Biophys Acta 1576: 1-14, 2002.
401. Schaffer JE. Fatty acid transport: the roads taken. Am J Physiol Endocrinol Metab 282: E239-E246, 2002.
402. Schaffer JE. Lipotoxicity: when tissues overeat. Curr Opin Lipidol 14: 281-287, 2003.
403. Schaper J, Froede R, Hein S, Buck A, Hashizume H, Speiser B, Friedl A, and Bleese N. Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy. Circulation 83: 504-514, 1991.
404. Scheubel RJ, Tostlebe M, Simm A, Rohrbach S, Prondzinsky R, Gellerich FN, Silber RE, and Holtz J. Dysfunction of mitochondrial respiratory chain complex I in human failing myocardium is not due to disturbed mitochondrial gene expression. J Am Coll Cardiol 40: 2174-2181, 2002.
405. Schmidt-Schweda S and Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci 99: 27-35, 2000.
406. Schofield RS and Hill JA. The use of ranolazine in cardiovascular disease. Expert Opin Invest Drugs 11: 117-123, 2002.
407. Schonekess BO, Allard MF, and Lopaschuk GD. Propionyl L-carnitine improvement of hypertrophied heart function is accompanied by an increase in carbohydrate oxidation. Circ Res 77: 726-734, 1995.
408. Schrauwen P, Saris WH, and Hesselink MK. An alternative function for human uncoupling protein 3: protection of mitochondria against accumulation of nonesterified fatty acids inside the mitochondrial matrix. FASEB J 15: 2497-2502, 2001.
409. Schulz H. Regulation of fatty acid oxidation in heart. J Nutr 124: 165-171, 1994.
410. Schwartz GG, Greyson C, Wisneski JA, and Garcia J. Inhibition of fatty acid metabolism alters myocardial high-energy phosphates in vivo. Am J Physiol Heart Circ Physiol 267: H224-H231, 1994.
411. Schwartz K, Boheler KR, de la BD, Lompre AM, and Mercadier JJ. Switches in cardiac muscle gene expression as a result of pressure and volume overload. Am J Physiol Regul Integr Comp Physiol 262: R364-R369, 1992.
412. Schwartz RG, Barrett EJ, Francis CK, Jacob R, and Zaret BL. Regulation of myocardial amino acid balance in the conscious dog. J Clin Invest 75: 1204-1211, 1985.
413. Sentex E, Helies-Toussaint C, Rousseau D, Lucien A, Ferrary E, and Grynberg A. Influence of trimetazidine on the synthesis of complex lipids in the heart and other target organs. Fundam Clin Pharmacol 15: 255-264, 2001.
414. Sentex E, Sergiel JP, Lucien A, and Grynberg A. Trimetazidine increases phospholipid turnover in ventricular myocyte. Mol Cell Biochem 175: 153-162, 1997.
415. Sentex E, Sergiel JP, Lucien A, and Grynberg A. Is the cytoprotective effect of trimetazidine associated with lipid metabolism? Am J Cardiol 82: 18K-24K, 1998.
416. Sharma N, Okere IC, McElfresh TA, King KL, Sterk JP, Huang H, Brunengraber DZ, Chandler MP, and Stanley WC. Regulation of glucose oxidation and pyruvate dehydrogenase activity during high cardiac energy expenditure: critical role for fatty acid oxidation. J Physiol 562: 593-603, 2004.
417. Sharov VG, Goussev A, Lesch M, Goldstein S, and Sabbah HN. Abnormal mitochondrial function in myocardium of dogs with chronic heart failure. J Mol Cell Cardiol 30: 1757-1762, 1998.
418. Sharov VG, Sabbah HN, Shimoyama H, Goussev AV, Lesch M, and Goldstein S. Evidence of cardiocyte apoptosis in myocardium of dogs with chronic heart failure. Am J Pathol 148: 141-149, 1996.
419. Sharov VG, Todor AV, Silverman N, Goldstein S, and Sabbah HN. Abnormal mitochondrial respiration in failed human myocardium. J Mol Cell Cardiol 32: 2361-2367, 2000.
420. Shen W, Asai K, Uechi M, Mathier MA, Shannon RP, Vatner SF, and Ingwall JS. Progressive loss of myocardial ATP due to a loss of total purines during the development of heart failure in dogs: a compensatory role for the parallel loss of creatine. Circulation 100: 2113-2118, 1999.
421. Simonsen S and Kjekshus JK. The effect of free fatty acids on myocardial oxygen consumption during atrial pacing and catecholamine infusion in man. Circulation 58: 484-491, 1978.
422. Slama M, Ahn J, Varagic J, Susic D, and Frohlich ED. Long-term left ventricular echocardiographic follow-up of SHR and WKY rats: effects of hypertension and age. Am J Physiol Heart Circ Physiol 286: H181-H185, 2004.
423. Smith CJ, Sun D, Hoegler C, Roth BS, Zhang X, Zhao G, Xu XB, Kobari Y, Pritchard K Jr, Sessa WC, and Hintze TH. Reduced gene expression of vascular endothelial NO synthase and cyclooxygenase-1 in heart failure. Circ Res 78: 58-64, 1996.
424. Solomon SD, St John SM, Lamas GA, Plappert T, Rouleau JL, Skali H, Moye L, Braunwald E, and Pfeffer MA. Ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarction. Circulation 106: 1251-1255, 2002.
425. Sparagna GC, Hickson-Bick DL, Buja LM, and McMillin JB. A metabolic role for mitochondria in palmitate-induced cardiac myocyte apoptosis. Am J Physiol Heart Circ Physiol 279: H2124-H2132, 2000.
426. Stanley WC. Myocardial lactate metabolism during exercise. Med Sci Sports Exercise 23: 920-924, 1991.
427. Stanley WC. Partial fatty acid oxidation inhibitors for stable angina. Expert Opin Invest Drugs 11: 615-629, 2002.
428. Stanley WC and Chandler MP. Energy metabolism in the normal and failing heart: potential for therapeutic interventions. Heart Fail Rev 7: 115-130, 2002.
429. Stanley WC, Hall JL, Stone CK, and Hacker TA. Acute myocardial ischemia causes a transmural gradient in glucose extraction but not glucose uptake. Am J Physiol Heart Circ Physiol 262: H91-H96, 1992.
430. Stanley WC, Hernandez LA, Spires D, Bringas J, Wallace S, and McCormack JG. Pyruvate dehydrogenase activity and malonyl CoA levels in normal and ischemic swine myocardium: effects of dichloroacetate. J Mol Cell Cardiol 28: 905-914, 1996.
431. Stanley WC and Hoppel CL. Mitochondrial dysfunction in heart failure: potential for therapeutic interventions? Cardiovasc Res 45: 805-806, 2000.
432. Stanley WC, Kivilo KM, Panchal AR, Hallowell PH, Bomont C, Kasumov T, and Brunengraber H. Post-ischemic treatment with dipyruvyl-acetyl-glycerol decreases myocardial infarct size in the pig. Cardiovasc Drugs Ther 17: 209-216, 2003.
433. Stanley WC, Lopaschuk GD, Hall JL, and McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc Res 33: 243-257, 1997.
434. Stanley WC, Lopaschuk GD, and McCormack JG. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 34: 25-33, 1997.
435. Stanley WC and Marzilli M. Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine. Fundam Clin Pharmacol 17: 133-145, 2003.
436. Stanley WC, Meadows SR, Kivilo KM, Roth BA, and Lopaschuk GD. beta-Hydroxybutyrate inhibits myocardial fatty acid oxidation in vivo independent of changes in malonyl-CoA content. Am J Physiol Heart Circ Physiol 285: H1626-H1631, 2003.
437. Stavinoha MA, RaySpellicy JW, Essop MF, Graveleau C, Abel ED, Hart-Sailors ML, Mersmann HJ, Bray MS, and Young ME. Evidence for mitochondrial thioesterase 1 as a peroxisome proliferator-activated receptor-α-regulated gene in cardiac and skeletal muscle. Am J Physiol Endocrinol Metab 287: E888-E895, 2004.
438. Stone CK, Holden JE, Stanley W, and Perlman SB. Effect of nicotinic acid on exogenous myocardial glucose utilization. J Nucl Med 36: 996-1002, 1995.
439. Stuart JA, Brindle KM, Harper JA, and Brand MD. Mitochondrial proton leak and the uncoupling proteins. J Bioenerg Biomembr 31: 517-525, 1999.
440. Suga H. Ventricular energetics. Physiol Rev 70: 247-277, 1990.
441. Sultan AM. Effects of diabetes and insulin on ketone bodies metabolism in heart. Mol Cell Biochem 110: 17-23, 1992.
442. Sundqvist KE, Hiltunen JK, and Hassinen IE. Pyruvate carboxylation in the rat heart. Role of biotin-dependent enzymes. Biochem J 257: 913-916, 1989.
443. Swanton EM and Saggerson ED. Effects of adrenaline on triacylglycerol synthesis and turnover in ventricular myocytes from adult rats. Biochem J 328: 913-922, 1997.
444. Swedberg K, Bristow MR, Cohn JN, Dargie H, Straub M, Wiltse C, and Wright TJ. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation 105: 1797-1803, 2002.
445. Szwed H, Sadowski Z, Elikowski W, Koronkiewicz A, Mamcarz A, Orszulak W, Skibinska E, Szymczak K, Swiatek J, and Winter M. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J 22: 2267-2274, 2001.
446. Tabbi-Anneni I, Helies-Toussaint C, Morin D, Bescond-Jacquet A, Lucien A, and Grynberg A. Prevention of heart failure in rats by trimetazidine treatment: a consequence of accelerated phospholipid turnover? J Pharmacol Exp Ther 304: 1003-1009, 2003.
447. Tada H, Thompson CI, Recchia FA, Loke KE, Ochoa M, Smith CJ, Shesely EG, Kaley G, and Hintze TH. Myocardial glucose uptake is regulated by nitric oxide via endothelial nitric oxide synthase in Langendorff mouse heart. Circ Res 86: 270-274, 2000.
448. Taegtmeyer H. Energy metabolism of the heart: from basic concepts to clinical applications. Curr Prob Cardiol 19: 59-113, 1994.
449. Taegtmeyer H, McNulty P, and Young ME. Adaptation and maladaptation of the heart in diabetes. Part I: general concepts. Circulation 105: 1727-1733, 2002.
450. 123I-BMIPP single-photon emission computed tomography in patients with congestive heart failure: effect of angiotensin II type-1 receptor blockade. Clin Cardiol 27: 204-210, 2004.
451. Tan FL, Moravec CS, Li J, Apperson-Hansen C, McCarthy PM, Young JB, and Bond M. The gene expression fingerprint of human heart failure. Proc Natl Acad Sci USA 99: 11387-11392, 2002.
452. Tang WH and Francis GS. Novel pharmacological treatments for heart failure. Expert Opin Invest Drugs 12: 1791-1801, 2003.
453. 18F]fluoro-6-thia-heptade-canoic acid and. J Nucl Med 42: 55-62, 2001.
454. Thampy KG. Formation of malonyl coenzyme A in rat heart. Identification and purification of an isozyme of A carboxylase from rat heart. J Biol Chem 264: 17631-17634, 1989.
455. Thiemermann C. Ligands of the peroxisome proliferator-activated receptor-gamma and heart failure. Br J Pharmacol 142: 1049-1051, 2004.
456. Thomassen A, Nielsen TT, Bagger JP, Pedersen AK, and Henningsen P. Antiischemic and metabolic effects of glutamate during pacing in patients with stable angina pectoris secondary to either coronary artery disease or syndrome X. Am J Cardiol 68: 291-295, 1991.
457. Thomassen AR. Myocardial uptake and effects of glutamate during non-ischaemic and ischaemic conditions. A clinical study with special reference to possible interrelationships between glutamate and myocardial utilization of carbohydrate substrates. Dan Med Bull 39: 471-488, 1992.
458. Thomassen AR, Mortensen PT, Nielsen TT, Falstie-Jensen N, Thygesen K, and Henningsen P. Altered plasma concentrations of glutamate, alanine and citrate in the early phase of acute myocardial infarction in man. Eur Heart J 7: 773-778, 1986.
459. Thomassen AK, Nielsen TT, Bagger JP, and Henningsen P. Myocardial exchanges of glutamate, alanine and citrate in controls and patients with coronary artery disease. Clin Sci 64: 33-40, 1983.
460. Thrasher JE, Cooper MD, and Dunaway GA. Developmental changes in heart and muscle phosphofructokinase isozymes. J Biol Chem 256: 7844-7848, 1981.
461. Thumelin S, Esser V, Charvy D, Kolodziej M, Zammit VA, McGarry D, Girard J, and Pegorier JP. Expression of liver carnitine palmitoyltransferase I and II genes during development in the rat. Biochem J 300: 583-587, 1994.
462. Tian R, Musi N, D'Agostino J, Hirshman MF, and Goodyear LJ. Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation 104: 1664-1669, 2001.
463. Tian R, Nascimben L, Kaddurah-Daouk R, and Ingwall JS. Depletion of energy reserve via the creatine kinase reaction during the evolution of heart failure in cardiomyopathic hamsters. J Mol Cell Cardiol 28: 755-765, 1996.
464. Treasure CB, Vita JA, Cox DA, Fish RD, Gordon JB, Mudge GH, Colucci WS, Sutton MG, Selwyn AP, and Alexander RW. Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation 81: 772-779, 1990.
465. Tsuura Y, Ishida H, Shinomura T, Nishimura M, and Seino Y. Endogenous nitric oxide inhibits glucose-induced insulin secretion by suppression of phosphofructokinase activity in pancreatic islets. Biochem Biophys Res Commun 252: 34-38, 1998.
466. Turcani M and Rupp H. Modification of left ventricular hypertrophy by chronic etomixir treatment. Br J Pharmacol 126: 501-507, 1999.
467. Ungar I, Gilbert M, Siegel A, Blain JM, and Bing RJ. Studies on myocardial metabolism. IV. Myocardial metabolism in diabetes. Am J Med 18: 385-396, 1955.
468. Unger RH. Lipotoxic diseases. Annu Rev Med 53: 319-336, 2002.
469. Unger RH. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 144: 5159-5165, 2003.
470. Unverferth DV, Lee SW, and Wallick ET. Human myocardial adenosine triphosphatase activities in health and heart failure. Am Heart J 115: 139-146, 1988.
471. Uren NG, Camici PG, Melin JA, Bol A, de Bruyne B, Radvan J, Olivotto I, Rosen SD, Impallomeni M, and Wijns W. Effect of aging on myocardial perfusion reserve. J Nucl Med 36: 2032-2036, 1995.
472. Van Bilsen M, van der Vusse GJ, Gilde AJ, Lindhout M, and Van Der Lee KA. Peroxisome proliferator-activated receptors: lipid binding proteins controlling gene expression. Mol Cell Biochem 239: 131-138, 2002.
473. Van der Vusse GJ, van Bilsen M, and Glatz JF. Cardiac fatty acid uptake and transport in health and disease. Cardiovasc Res 45: 279-293, 2000.
474. Vanoverschelde JL, Wijns W, Kolanowski J, Bol A, Decoster PM, Michel C, Cogneau M, Heyndrickx GR, Essamri B, and Melin JA. Competition between palmitate and ketone bodies as fuels for the heart: study with positron emission tomography. Am J Physiol Heart Circ Physiol 264: H701-H707, 1993.
475. Vedia L, McDonald B, Reep B, Brune B, Di Silvio M, Billiar TR, and Lapetina EG. Nitric oxide-induced S-nitrosylation of glyceraldehyde-3-phosphate dehydrogenase inhibits enzymatic activity and increases endogenous ADP-ribosylation. J Biol Chem 267: 24929-24932, 1992.
476. Vega RB, Huss JM, and Kelly DP. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol 20: 1868-1876, 2000.
477. Ventura-Clapier RF, Garnier A, and Veksler V. Energy metabolism in heart failure. J Physiol 555: 1-13, 2004.
478. Vidal-Puig AJ, Grujic D, Zhang CY, Hagen T, Boss O, Ido Y, Szczepanik A, Wade J, Mootha V, Cortright R, Muoio DM, and Lowell BB. Energy metabolism in uncoupling protein 3 gene knockout mice. J Biol Chem 275: 16258-16266, 2000.
479. Vincent G, Bouchard B, Khairallah M, and des Rosiers C. Differential modulation of citrate synthesis and release by fatty acids in perfused working rat hearts. Am J Physiol Heart Circ Physiol 286: H257-H266, 2004.
480. Wallhaus TR, Taylor M, DeGrado TR, Russell DC, Stanko P, Nickles RJ, and Stone CK. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation 103: 2441-2446, 2001.
481. Wang CH, Weisel RD, Liu PP, Fedak PW, and Verma S. Glitazones and heart failure: critical appraisal for the clinician. Circulation 107: 1350-1354, 2003.
482. Warshaw JB. Cellular energy metabolism during fetal development. 1. Oxidative phosphorylation in the fetal heart. J Cell Biol 41: 651-657, 1969.
483. Warshaw JB. Cellular energy metabolism during fetal development. IV. Fatty acid activation, acyl transfer and fatty acid oxidation during development of the chick and rat. Dew Biol 28: 537-544, 1972.
484. Watson PS, Scalia GM, Galbraith A, Burstow DJ, Bett N, and Aroney CN. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. J Am Coll Cardiol 33: 1549-1552, 1999.
485. Weis BC, Cowan AT, Brown N, Foster DW, and McGarry JD. Use of a selective inhibitor of liver carnitine palmitoyltransferase I (CPT I) allows quantification of its contribution to total CPT I activity in rat heart. Evidence that the dominant cardiac CPT I isoform is identical to the skeletal muscle enzyme. J Biol Chem 269: 26443-26448, 1994.
486. Weiss J and Hiltbrand B. Functional compartmentation of glycolytic versus oxidative metabolism in isolated rabbit heart. J Clin Invest 75: 436-447, 1985.
487. + channels in isolated guinea pig cardiac myocytes. Science 238: 67-69, 1987.
488. + channels. Evidence for preferential regulation by glycolysis. J Gen Physiol 94: 911-935, 1989.
489. Werner JC and Sicard RE. Lactate metabolism of isolated, perfused fetal, and newborn pig hearts. Pediatr Res 22: 552-556, 1987.
490. Whitehouse S, Cooper RH, and Randle PJ. Mechanism of activation of pyruvate dehydrogenase by dichloroacetate and other halogenated carboxylic acids. Biochem J 141: 761-774, 1974.
491. Wieland O, Siess E, Schulze-Wethmar FH, von Funcke HG, and Winton B. Active and inactive forms of pyruvate dehydrogenase in rat heart and kidney: effect of diabetes, fasting, and refeeding on pyruvate dehydrogenase interconversion. Arch Biochem Biophys 143: 593-601, 1971.
492. 13C3]lactate: a new approach for investigating human myocardial metabolism during ischemia. J Am Coll Cardiol 5: 1138-1146, 1985.
493. Wisneski JA, Gertz EW, Neese RA, Gruenke LD, Morris DL, and Craig JC. Metabolic fate of extracted glucose in normal human myocardium. J Clin Invest 76: 1819-1827, 1985.
494. 14C-labeled substrates in humans. J Clin Invest 79: 359-366, 1987.
495. Wisneski JA, Stanley WC, Neese RA, and Gertz EW. Effects of acute hyperglycemia on myocardial glycolytic activity in humans. J Clin Invest 85: 1648-1656, 1990.
496. Wu P, Peters JM, and Harris RA. Adaptive increase in pyruvate dehydrogenase kinase 4 during starvation is mediated by peroxisome proliferator-activated receptor alpha. Biochem Biophys Res Commun 287: 391-396, 2001.
497. Xia Y, Buja LM, and McMillin JB. Change in expression of heart carnitine palmitoyltransferase I isoforms with electrical stimulation of cultured rat neonatal cardiac myocytes. J Biol Chem 271: 12082-12087, 1996.
498. Xie YW, Shen W, Zhao G, Xu X, Wolin MS, and Hintze TH. Role of endothelium-derived nitric oxide in the modulation of canine myocardial mitochondrial respiration in vitro. Implications for the development of heart failure. Circ Res 79: 381-387, 1996.
499. Xing Y, Musi N, Fujii N, Zou L, Luptak I, Hirshman MF, Goodyear LJ, and Tian R. Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative alpha2 subunit of AMP-activated protein kinase. J Biol Chem 278: 28372-28377, 2003.
500. 2+ transport. Circ Res 77: 88-97, 1995.
501. Yagyu H, Chen G, Yokoyama M, Hirata K, Augustus A, Kako Y, Seo T, Hu Y, Lutz EP, Merkel M, Bensadoun A, Homma S, and Goldberg IJ. Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest 111: 419-426, 2003.
502. Yamauchi S, Takeishi Y, Minamihaba O, Arimoto T, Hirono O, Takahashi H, Miyamoto T, Nitobe J, Nozaki N, Tachibana H, Watanabe T, Fukui A, and Kubota I. Angiotensin-converting enzyme inhibition improves cardiac fatty acid metabolism in patients with congestive heart failure. Nucl Med Commun 24: 901-906, 2003.
503. 123I BMIPP SPECT: correlation with clinicopathological findings and clinical course. Heart 81: 153-159, 1999.
504. Ye Y, Gong G, Ochiai K, Liu J, and Zhang J. High-energy phosphate metabolism and creatine kinase in failing hearts: a new porcine model. Circulation 103: 1570-1576, 2001.
505. Yokoyama M, Yagyu H, Hu Y, Seo T, Hirata K, Homma S, and Goldberg IJ. Apolipoprotein B production reduces lipotoxic cardiomyopathy: studies in heart specific lipoprotein lipase transgenic mouse. J Biol Chem 279: 4204-4211, 2004.
506. Young LH, Coven DL, and Russell RR III. Cellular and molecular regulation of cardiac glucose transport. J Nucl Cardiol 7: 267-276, 2000.
507. Young LH, Renfu Y, Russell R, Hu X, Caplan M, Ren J, Shulman GI, and Sinusas AJ. Low-flow ischemia leads to translocation of canine heart GLUT-4 and GLUT-1 glucose transporters to the sarcolemma in vivo. Circulation 95: 415-422, 1997.
508. Young ME, Goodwin GW, Ying J, Guthrie P, Wilson CR, Laws FA, and Taegtmeyer H. Regulation of cardiac and skeletal muscle malonyl-CoA decarboxylase by fatty acids. Am J Physiol Endocrinol Metab 280: E471-E479, 2001.
509. Young ME, Laws FA, Goodwin GW, and Taegtmeyer H. Reactivation of peroxisome proliferator-activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart. J Biol Chem 276: 44390-44395, 2001.
510. Young ME, McNulty P, and Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes. Part II: potential mechanisms. Circulation 105: 1861-1870, 2002.
511. Young ME, Patil S, Ying J, Depre C, Ahuja HS, Shipley GL, Stepkowski SM, Davies PJ, and Taegtmeyer H. Uncoupling protein 3 transcription is regulated by peroxisome proliferator-activated receptor (alpha) in the adult rodent heart. FASEB J 15: 833-845, 2001.
512. Young ME, Radda GK, and Leighton B. Nitric oxide stimulates glucose transport and metabolism in rat skeletal muscle in vitro. Biochem J 322: 223-228, 1997.
513. Zammit VA, Fraser F, and Orstorphine CG. Regulation of mitochondrial outer-membrane carnitine palmitoyltransferase (CPT I): role of membrane-topology. Adv Enzyme Regul 37: 295-317, 1997.
514. Zarain-Herzberg A and Rupp H. Therapeutic potential of CPT I inhibitors: cardiac gene transcription as a target. Expert Opin Invest Drugs 11: 345-356, 2002.
515. Zarain-Herzberg A, Rupp H, Elimban V, and Dhalla NS. Modification of sarcoplasmic reticulum gene expression in pressure overload cardiac hypertrophy by etomoxir. FASEB J 10: 1303-1309, 1996.
516. Zhang J, Merkle H, Hendrich K, Garwood M, From AH, Ugurbil K, and Bache RJ. Bioenergetic abnormalities associated with severe left ventricular hypertrophy. J Clin Invest 92: 993-1003, 1993.
517. Zhang J and Snyder SH. Nitric oxide stimulates auto-ADP-ribosylation of glyceraldehyde-3-phosphate dehydrogenase. Proc Natl Acad Sci USA 89: 9382-9385, 1992.
518. Zhang J, Toher C, Erhard M, Zhang Y, Ugurbil K, Bache RJ, Lange T, and Homans DC. Relationships between myocardial bioenergetic and left ventricular function in hearts with volume-overload hypertrophy. Circulation 96: 334-343, 1997.
519. Zhou L, Salem JE, Saidel GM, Stanley WC, and Cabrera ME. Mechanistic model of cardiac energy metabolism predicts localization of glycolysis to cytosolic subdomain during ischemia. Am J Physiol Heart Circ Physiol 288: H2400-H2411, 2005.
520. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, and Unger RH. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 97: 1784-1789, 2000.